Seton Hall University

eRepository @ Seton Hall
Seton Hall University Dissertations and Theses
(ETDs)

Seton Hall University Dissertations and Theses

2005

Synthesis of Novel Porphyrazines and Binding Studies to DNA
Quadruplexes
Carlos Ramirez
Seton Hall University

Follow this and additional works at: https://scholarship.shu.edu/dissertations
Part of the Biochemistry Commons, and the Organic Chemistry Commons

Recommended Citation
Ramirez, Carlos, "Synthesis of Novel Porphyrazines and Binding Studies to DNA Quadruplexes" (2005).
Seton Hall University Dissertations and Theses (ETDs). 1484.
https://scholarship.shu.edu/dissertations/1484

SYNTHESIS OF NOVEL PORPHYRAZINES
AND
BINDING STUDIES TO DNA QUADRUPLEXES

A Dissertation
In the Department o f Chemistry and Biochemistry submitted
to the faculty o f the Graduate School o f Arts and Science
in partialfulfillm ent o f the requirements fo r the

degree o f

Doctor O f Philosophy
In Chemistry
at

SETON HALL UNIVERSITY
by
Carlos Ramirez

DECEMBER, 2005

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

We certify that we have read this thesis and that in our opinion it is
adequate in scientific scope and quality as a dissertation for the degree of
Doctor of Philosophy.

APPROVED

Signature
Dr. Richard D. Sheardy, Research Advisei

Signature
U
Dr. James E. Hanson

Signature
Dr. Cecilia Marzabadi

—

Tftj}A->/jJy7rJU
&

Signature
_____________________________
Approved forlfie Department of Chemistry and Biochemistry
Dr. Nicholas H. Snow, Chairman, Department of Chemistry and Biochemistry

ii

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Acknowledgements

V

List of Tables

vi

List of Figures

vii

List of Abbreviations

xiv

Abstract

XV

Chapter 1.

Introduction

1

Chapter II.

Historical

8

I.

Telomere and Telomerase

14

II.

Polymorphic nature of DNA

18

III.

DNA quadruplexes

21

IV.

The origin of Phthalocyanines

38

V.

Telomeres and cancer

39

VI.

DNA-Drug Interactions

41

I

Intercalating drugs

41

II.

Groove binding drugs

47

III.

Electrostatic interactions

49

VII.

Porphyrins and DNA

50

VIII.

Porphyrins and DNA quadruplexes

56

Chapter III.
I

n.

Theory, Methods and Materials
60

Theory

81

Methods and Materials

Chapter IV.

Results and Discussion

iii

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

100

Chapter V.

Conclusions

149

References

152

iv

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ACKNOWLEDGEMENTS

I am indebted to Dr. Richard D. Sheardy, for his guidance and patience
while I was at Seton Hall University. His encouragement and ideas have been
very insightful. I am greatful to Dr. Alex Fadeev, Dr. James E. Hanson, Dr.
Cecilia Marzabadi, Dr. Nicholas Snow and to Dr. John Sowa for their opinions
and encouragement while pursuing my degree. I also thank Dr. Rash Mathur for
his advice and enlightment. I would also like to thank Dr. Nailia Vodovskaia. I
would also like to thank my Father Dr. Alejandro Ramirez Miller and my son
John Carlos Ramirez for their contributions and encouragement to never give
up.

v

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

LIST OF TABLES

Table 1.

Physical properties o f DNA oligonucleotides used for
competitive dialysis study.

Table 2.

Electronic Spectral Data o f the Porphyrazines in DI Water
8 = dm3m or1cm 1 *= In 10% acetic acid.

Table 3.

Effect o f changing wavelength (AX) on DNA
Porphyrazines.

vi

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

LIST OF FIGURES

Figure 1.

A single strand of DNA o f four nucleotide residues14. Mahrukh
Azam (2000).

Figure 2.

Watson-Crick base pairing in double-stranded DNA. The curved
lines represent hydrogen bonds and are in the direction o f the
hydrogen bond acceptor. Interatom hydrogen bond distances are
given in angstroms. Mahrukh Azam (2000).

Figure 3.

A-DNA double helix. Figure adapted from Mathews and van
Holde (1990). Mahrukh Azam (2000).

Figure 4.

B-DNA double helix. Figure adapted from Mathews and van
Holde (1990). Mahrukh Azam (2000).

Figure 5.

Mechanism by which telomerase adds short telomere segments to
the 3’ end o f chromosomal DNA. These segments, which can
then be primed, allow 5’ —*■3’ synthesis on the lagging strand.
Mahrukh Azam (2000).

Figure 6.

Z-DNA double helix. Figure adapted from Mathews and van
Holde (1990). Mahrukh Azam (2000).

Figure 7.

Formation o f DNA triplex from Non-Watson-Crick base- pairing
for TAT (left), TAA(center) and CGG (right) from Hoogsteen
base pairing. Mahrukh Azam (2000).

Figure 8.

Guanine-quartet hydrogen-bonding array as proposed by Gellert,
196224. R=H for guanine and R=phospho-ribose for nucleic
acids. Mahrukh Azam (2000).

Figure 9.

Cyclic array o f four guanine bases (a); Quadruple Helical
Structure (b); G4 T4 G4 in Na+ solution determined by NMR (c);
G4 T4 G4 in K+ solution determined by X-ray Crystallography (d).
[Williamson, 1994], Mahrukh Azam (2000).

Figure 10.

Schematic o f a back-to-back arrangement o f a G-8 DNA
complex formed from a G-4 DNA. Mahrukh Azam (2000).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 11.

Schematic o f back-to-front (top) and back-to-back (bottom)
models for G-8 DNA which involve bonding of two G-4 DNA
units via quartet formation by slipped guanines from either unit.
The unbonded G’s are circled. Mahrukh Azam (2000).

Figure 12.

Schematics for G4-DNA formed by T„G3 (A) and T„.iG3 T (B)
and the sugarcane type model o f G8-DNA formed by TnG3 (C).
Mahrukh Azam (2000).

Figure 13.

Plot of the temperature at which 10% o f the quadruplex
population has denatured (To.im) versus the van der Waals radius
of the corresponding hydrated ions. Mahrukh Azam (2000).

Figure 14.

(a) G-quartet with a model ion in the pocket, which is formed by
four oxygen 06-atoms, (b) Potassium ion in the twisted cage
formed by eight 06-atoms. Wireframe presentations o f the
d[GGGG] 4 quadruplex structure, (c) View perpendicular to the
helical axis; (d) axial view. One ion is shown which is trapped in
the central cage35. Mahrukh Azam (2000).

Figure 15.

(A) Energy minimized quadruplexed structure of the sequence
CIT4G4. Eight planes containing four G’s and four T’s. (B) Top
view of the stacking at the T4-G5 steps. Each T stacks partially
below two G-bases in the G5 layer, in an interaction that seems
to be stabilized by a K+ ion located between the planes38.
Mahrukh Azam (2000).

Figure 16.

(Top) A depiction o f the tertiary structure o f the aptamer is
shown. The dashed lines indicate the location o f the G-tetrads.
(Bottom) A depiction o f a syn-anti-syn-anti tetrad.
Mahrukh Azam (2000).

Figure 17.

Structure o f parallel stranded quadruplex T4G4 (A), hairpin
C4T4G4T4G4 (B), and bimolecular quadruplex G4T2G4 (C).
Mahrukh Azam (2000).

Figure 18.

Schematic representation o f the bridging o f successive
quadruplexes by two strands, resulting in a linear superstructure
with the individual tetrads and the periodic “pockets”.
Mahrukh Azam (2000).

Figure 19.

AFM images o f self-assembling sequence d(GtT 2 Gi) under
different salt conditions47. Mahrukh Azam (2000).

vin

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 20.

Schematic representation o f the pocket created in the selfassembly of DNA oligomers possessing G4 T2 G4 .
Mahrukh Azam (2000).

Figure 21.

Sketch o f B-DNA (left) and Drug-DNA complex (right).
Mahrukh Azam (2000).

Figure 22.

Examples o f classical intercalators: Duanomycin, R=H (left) and
Ethidium bromide (right). Mahrukh Azam (2000).

Figure 23.

Structures o f different porphyrins TMPyP4, MTMPyP4,
TMPyP2 and their metal derivatives. Mahrukh Azam (2000).

Figure 24.

Components o f an Atomic Force Microscopy Instrument.
Bottomley (2002).

Figure 25.

DNA strand before exposure to ethidium bromide (A) and
after exposure to ethidium bromide (B). Bottomley (2002).

Figure 26.

Schematic diagram o f the experimental arrangement for the
competition dialysis assay. Chaires (2002).

Figure 27.

UV/visible absorbance spectrum o f TEPPI.

Figure 28.

UV/visible absorbance versus Moles/liter o f TEPPI.

Figure 29.

UV/visible absorbance spectrum o f MnTEPPI.

Figure 30.

UV/visible absorbance versus Moles/liter o f MnTEPPI.

Figure 31.

UV/visible absorbance spectrum o f CoTEPPI.

Figure 32.

UV/visible absorbance versus Moles/liter o f CoTEPPI.

Figure 33.

UV/visible absorbance spectrum o f CuTEPPI.

Figure 34.

UV/visible absorbance versus Moles/liter of CuTEPPI.

Figure 35.

UV/visible absorbance spectrum o f ZnTEPPI.

Figure 36.

UV/visible absorbance versus Moles/liter o f ZnTEPPI.

Figure 37

UV/visible absorbance spectrum o f TPP.

Figure 38.

UV/visible absorbance versus Moles/liter o f TPP.

ix

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 39.

UV/visible spectra for the titration of TEPPI in the presence
of calf thymus.

Figure 40.

UV/visible spectra of calf thymus + TEPPI fully bound and
TEPPI unbound.

Figure 41.

UV/visible spectra for the titration of TEPPI in the presence o f
d(T4G4).

Figure 42.

UV/visible spectra o f d(T4G4) + TEPPI folly bound and TEPPI
unbound.

Figure 43.

UV/visible spectra for the titration o f TEPPI in the presence o f
d(G4T4G4).

Figure 44.

UV/visible spectra o f d(G4T4G4) + TEPPI folly bound and
TEPPI unbound.

Figure 45.

UV/visible spectra for the titration of TEPPI in the presence of
d(G2T2G2TGT G2T2G2).

Figure 46.

UV/visible spectra o f d(G2T2G2TGT G2T2G2HTEPPI folly
bound and TEPPI unbound.

Figure 47.

UV/visible spectra for the titration of TEPPI in the presence o f
d(T4G4T).

Figure 48.

UV/visible spectra o f d(T4G4T) + TEPPI folly bound and
TEPPI unbound.

Figure 49.

UV/visible spectra for the titration o f ZnTEPPI in the presence
of calf thymus.

Figure 50.

UV/visible spectra o f calf thymus + ZnTEPPI folly bound and
ZnTEPPI unbound.

Figure 51.

UV/visible spectra for the titration of ZnTEPPI in the presence
o f d(T4G4).

Figure 52.

UV/visible spectra of d(T4G4) + ZnTEPPI folly bound and
ZnTEPPI unbound.

Figure 53.

UV/visible spectra for the titration o f ZnTEPPI in the presence
o f d(G4T4G4).

x

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 54.

UV/visible spectra o f d(G 4 T4G4 ) + ZnTEPPI fully bound and
ZnTEPPI unbound.

Figure 55.

UV/visible spectra for the titration of ZnTEPPI in the presence
of d(G2T2G2TGT G2T2G2).

Figure 56.

UV/visible spectra o f d(G2T2G2TGT G2T2G2)+ ZnTEPPI folly
bound and ZnTEPPI unbound.

Figure 57.

UV/visible spectra for the titration of ZnTEPPI in the presence
ofd(T4G4T).

Figure 58.

UV/visible spectra of d(T4G4T) + ZnTEPPI folly bound and
TEPPI unbound.

Figure 59.

UV/visible spectra for the titration of CoTEPPI in the presence
of calf thymus.

Figure 60.

UV/visible spectra o f calf thymus + CoTEPPI folly bound and
CoTEPPI unbound.

Figure 61.

UV/visible spectra for the titration o f CoTEPPI in the presence
ofd(T4G4).

Figure 62.

UV/visible spectra o f d(T4G4) + CoTEPPI folly bound and
CoTEPPI unbound.

Figure 63.

UV/visible spectra for the titration of CoTEPPI in the presence
ofd(G4T4G4).

Figure 64.

UV/visible spectra o f d(G4 T4G4) + CoTEPPI folly bound and
CoTEPPI unbound.

Figure 65.

UV/visible spectra for the titration of CoTEPPI in the presence
of d(G2T2G2TGT G2T2G2).

Figure 66.

UV/visible spectra of d(G2T2G2 TGT G2T2G2)+ CoTEPPI folly
bound and CoTEPPI unbound.

Figure 67.

UV/visible spectra for the titration o f CoTEPPI in the presence
of d(T4G4 T).

Figure 68.

UV/visible spectra o f d(T4G»T) + CoTEPPI folly bound and
CoTEPPI unbound.

xi

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 69.

%Hypochromicity (+) and %Hyperchromicity (-) o f the soret
band for TEPPI, MnTEPPI, CoTEPPI, CuTEPPI and ZnTEPPI.

Figure 70.

AFM Image o f control linearized plasmid prS316.
(Bottomley, 2004).

Figure 71.

AFM o f CuTEPPI at lOuM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 72.

AFM of CuTEPPI at 20uM in the presence of linearized
plasmid prS316. (Bottomley, 2004).

Figure 73.

AFM of CuTEPPI at 30uM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 74.

AFM o f CuTEPPI at 60uM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 75.

AFM o f CuTEPPI at lOOuM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 76.

AFM o f CuTEPPI at 300uM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 77.

AFM o f CoTEPPI at lOuM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 78.

AFM of CoTEPPI at 30uM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 79.

AFM o f CoTEPPI at 524.5uM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 80.

AFM o f MnTEPPI at 300uM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 81.

AFM o f ZnTEPPI at 300uM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 82.

AFM of CoTEPPI at 3000uM in the presence o f linearized
plasmid prS316. (Bottomley, 2004).

Figure 83.

# DNA Strands % versus DNA length (pm) from porphyrazine
study using AFM. (Bottomley, 2004).

xii

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 84.

Comparison of DNA lengthening from CoTEPPI and
CuTEPPI to the Ethidium Bromide binding curve.
(Bottomley, 2004).

Figure 85.

Competitive dialysis diagram showing bound (pm) porphyrazine
to oligonucleotide DNA.

Figure 86.

Competitive dialysis diagram showing bound (pm) porphyrazine
to oligonucleotide DNA.

Figure 87.

(Cb - Cb CTDNA) - The difference in the amount bound
relative to the amount bound to calf thymus DNA.

Figure 88.

(Cb - Cb T4 ° 4 ) = The difference in the amount bound
relative to the amount bound to d(T4 G4 ).

Figure 89.

Intact reverse transcriptase Rnase H. % inhibition at 6 uM and
10 uM concentration. (Pamiak 2004).

Figure 90.

Concentration o f Porphyrazine required for 50% inhibition
O f viral replication o f HTV infected cells. (EC50).
(Pamiak 2004).

Figure 91.

Concentration o f porphyrazine required for 50% cell kill
o f the uninfected cells. (CC50). (Pamiak 2004).

Figure 92.

CC50/EC50 measure o f the porphyrazine theurapeutic index.
(Pamiak 2004).

xiii

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

LIST OF ABBREVATIONS

AFM

Atomic force microscopy

DNA

Deoxyribonucleic acid

TPP

Tetrapyridino porphyrazine

TEPPC1

Tetraethanol pyridino porphyrazine Chloride

TEPPI

Tetraethanol pyridino porphyrazine Iodide

CoTEPPI

Cobalt Tetraethanol pyridino porphyrazine Iodide

CuTEPPI

Copper Tetraethanol pyridino porphyrazine
Iodide

MnTEPPI

Manganese Tetraethanol pyridino porphyrazine
Iodide

ZnTEPPI

Zinc Tetraethanol pyridino porphyrazine Iodide

CuTMPyP

Copper complex o f (4-N-methylpyridyl)-porphine

TMPyP2

(2-N-methylpyridyl)-porphine

dA, A

Deoxyadenine

dG, G

Deoxyguanine

dC, C

Deoxycytosine

dT, T

Deoxythymidine

U

Uridine

Guo-3’-P

Guanosine 3’ phosphate

Guo-5’-P

Guanosine 5’ phosphate

CPG

Dinucleotide of C and G

xiv

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER I
INTRODUCTION

Telomeres and telomerase are at the forefront of much nucleic acid research for
they hold the key to unraveling how DNA and drugs interact.15 Telomeres are proteinnucleic acid structures that cap the ends o f eukaryotic chromosomes. These terminal
structures, composed o f repetitive arrays of guanine-rich DNA, such as TTAGGG found
in humans, are specific targets for telomere-binding proteins; they play key roles in
protecting the chromosome from being destroyed

and degraded. Research has also

shown that telomere maintenance is an important regulator of cell life span.16 Activation
o f telomerase, a dedicated reverse transcriptase that synthesizes telomeric sequences, has
been linked with cancer, and research by many groups indicate that telomeres and
telomerase perform important functions in both curtailing and expediting changes in
malignant tum ors.17
The telomeric DNA can reach a length o f 15,000 base pairs. Telomeres work by
preventing chromosomes from losing base pair sequences at their ends. They also stop
chromosomes from connecting to each other. When a cell divides, 25-200 base pairs per
division o f the telomere is lost.18 As the telomere becomes shorter, the chromosome
reaches a certain length and at this point it can no longer replicate. The cell becomes
aged and dies by a process called apoptosis.19 Telomere activity is controlled by two
mechanisms: erosion and addition. Erosion occurs each time a cell divides. Addition is
determined by the activity o f telomerase RNA subunits that elongates chromosomes by
adding in humans TTAGGG sequences to the end of existing chromosomes.20

1
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Telomerase is found in fetal issues, adult germ cells and also in tumor cells. Telomerase
activity is regulated during growth and has a very small, unchanging activity in somatic
cells. Since somatic cells do not usually use telomerase, they age.21 The result o f aging
cells is an aging body. When telomerase is activated in a cell, they will continue to grow
and divide. This immortal cell theory is important in two areas o f research: aging and
cancer.22 Cellular aging, or senescence, is the process by which a cell becomes old and
dies. It is due to the shortening o f chromosomal telomeres to the point that the
chromosome reaches a critical length. Cells are constantly aging. Having the ability to
make the body's cells live forever would be the key to a longer life. Basic research on
telomerase is the key to unraveling how a cell ages and the process by which it ages.23
Telomerase research could unlock the path to discoveries related to the aging process,
which in turn could help in the process o f making new therapeutic agents that target
senility.
Cancer cells are malignant cells. The malignant cells multiply until they form a
tumor that grows without control. Telomerase has been detected in human cancer cells
and is found to be 10-20 times more active than in normal body cells.24 This provides a
selective growth advantage to many types of tumors. If telomerase activity could be
stopped, then telomeres in cancer cells would shorten, just like they do in normal body
cells. This would stop cancer cells from dividing without control in the early stages of
development. If a tumor has already developed, it may be removed and anti-telomerase
therapy could be administered to prevent it from coming back 25 Being able to prevent
telomerase from performing its function would change cancer cells from "immortal" to
"mortal". Having an understanding of telomeres and telomerase,is the key o f discovering

2
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many new drugs and therapies 26 The future o f research in the area o f telomerase could
reveal insight into how to slow the aging process and destroy cancer. Telomerase
enzyme is clearly required in human cells to bypass senescence and crisis responses.
During tumor genesis, reactivation of telomerase is likely important in rescuing cells
from crisis.27
G-quadruplex structures can vary in a number of different ways, including strand
stoichiometry and strand orientation, but there is greatest variation at the ends, which if
capped by looping structures can consist o f any of the four bases in loop sizes of 2 to
about 6 bases. The interconversion between double- or single-stranded DNA and Gquadruplex in cells is dependent upon chaperone proteins, such as the subunit of the
telomere binding protein from Oxytricha that facilitate G- quadruplex formation, as well
as upon helicases such as Sgsl from yeast, which resolve these structures 28 Proteins such
as RAP-1 are also known that bind to and stabilize these G-quadruplex structures.29
The facile interconversion, at physiological conditions, between double- or single
stranded DNA and G-quadruplex structures, together with the known occurrence of
binding or chaperone proteins, makes these secondary DNA structures attractive
candidates for biological signaling molecules, based upon their unique molecular
recognition properties in contrast to duplex DNA.30 In many respects, the folding of
single-stranded DNA into G-quadruplex structures is analogous to the folding o f peptides
into proteins, as the primary base sequence is the main determinant o f the folded Gquadruplex structure. When the genetic information encoded by DNA must be passed on
to the next generation, a mechanism for interconversion between secondary DNA and
duplex DNA structures must be available. This requirement for interconversion between

3
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the different forms o f DNA points to a potential weakness in the system, as secondary
"trapped" DNA structures might disrupt signaling mechanisms or prevent replication31
The original purpose for the design o f G-quadruplex-interactive molecules was
inhibition of telomerase by sequestration of the single-stranded DNA primer as a Gquadruplex structure, thus eliminating the substrate required for the reverse transcriptase
activity o f telomerase.32 This approach to inhibition o f telomerase is in contrast to that
involving catalytic inhibition o f the enzyme. Both approaches to inhibition o f telomerase
have inherent problems. The selectivity imparted by the absence of a requirement for
telomerase from all but germ-line cells in normal tissues gives rise to the anticipated
selective toxicity to cancer cells that uniquely require this activity for telomere
maintenance and survival; however, the prolonged time for sufficient telomere erosion is
potentially a major therapeutic problem 33 In contrast, telomere disruption by stabilization
o f G-quadruplex structures lacks the selectivity associated with the unique requirement
for telomerase in cancer cells and depends instead upon whether or not telomere
disruption is more detrimental to cancer cells than to normal cells. As yet, data are
lacking that would define such differences, although it is likely that the onset o f events
triggered by telomere disruption is much fester than those mediated by telomerase
inhibition. So, strategies that depend purely upon disruption of telomeres lack a solid
rationale for selective therapeutics for cancer. Nevertheless, encouraging data are
emerging that shows that despite a lack o f significant telomere shortening, which would
result from the inhibition o f telomerase, telomeric disruption, presumably through
trapping o f G-quadruplex structures, results in short-term biological effects such as
formation o f anaphase bridges, apoptosis, and cell death.34 A recent report from the

4
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Greider research laboratory has demonstrated that it is the shortest telomere, not average
telomere length, that determines chromosomal stability and cell viability.35 Cancer cells
with just one abnormally short telomere will presumably be made more sensitive than
normal cells to catalytic inhibitors of telomerase. They may also be more sensitive to Gquadruplex-interactive compounds if telomere modification by these agents leads to
degradation of the telomere.36
G-quadruplex-forming sequences are also found in a number o f transcriptional
regulatory regions o f important oncogenes, including c-myc, c-myb, c-fos and c-abl.37
Because o f the polypurine-polypyrimidine nature o f these duplex sequences, which
contain four or more runs o f clusters of three or more guanines on the purine-rich strand,
they often show a single-stranded character and hence are nuclease hypersensitivity
regions. In the c-myc promoter, the purine- and pyrimidine- rich strands bind
transcription factors (CNBP and hnRNP) required for transcriptional activation.38 As
these elements can also form G-quadruplex and i- motif structures, it is possible that
these secondary DNA structures inactivate transcription, and their conversion to the
duplex region is required for transcriptional activation. G-quadruplex-stabilizing
molecules that would prevent this transition would therefore inactivate c-myc expression.
As down-regulation o f c-myc expression in tumor cells by only 30% leads to a dramatic
reduction to ras and raf transformation, the selective stabilization of G-quadruplex
structures in the promoter regions o f c-myc should lead to selective effects on cancer
cells.39
Our group has been investigating the synthesis and binding of metallic and
nonmetallic cationic porphyrazines, especially the nonmetallated tetraethanol-pyridino

5
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porphyrazine iodide, (TEPPI), and metallated tetraethanol-pyridino porphyrazines iodide
having Mn, Co, Cu, and Zn as the center metals (MTEPPI) with polymorphic DNA
structures. Physical properties of these porphyrazines such as molecular dimensions,
presence of a chromophore, outside positive charges and water solubility make them
favorable for intercalating into, or stacking, the major or minor groove or by electrostatic
forces with multistranded structures.40 Interactions of these porphyrazines with
multistranded DNA have been explored, especially the binding modes via UV/VIS
studies, competitive dialysis studies, competitive binding studies with ethidium bromide,
AFM studies, and specifically their utility as Reverse Transcriptase inhibitors in HIV.
This research has shown that porphyrazines have no binding affinity for single stranded
DNA, and that there is more affinity towards DNA quadruplexes than DNA duplexes. It
has also been demonstrated that TEPPI and MTEPPI porphyrazines are able to inhibit
Reverse transcriptase RNase and reverse transcriptase polymerase.
Initially, we became interested in synthesizing model compounds that would
interact with different polymorphic forms o f DNA including self-assembling
quadruplexes and to exploit their activity as HIV inhibitors. After three years, we were
able to find facile and novel routes to the synthesis o f nometallated and metallated
porphyrazines. After fully characterizing these porphyrazines, our next task was to
determine if these molecules bind to polymorphic DNA structures and to demonstrate
their utility as potential therapeutic agents for HTV.
The binding studies and competitive dialysis studies were monitored by visible
absorption spectroscopy. Competitive binding studies with ethidium bromide were
monitored by atomic force microscopy. The utility o f these porphyrazines as potential

6
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HIV inhibitors was done at Carnegie Mellon Institute of Viral Diseases under the
direction of Dr. Mike Pamiak
It must be noted that the main thrust of this project was to synthesize novel
porphyrazines and to demonstrate if these porphyrazines can selectively recognize and
stabilize, single, double or multistranded DNA quadruplexes, which in turn could inhibit
telemerase activity. Hence, the focus of this research was to investigate if these
porphyrazines would bind and selectively recognize multistranded DNA. This effort was
to further our understanding of how anticancer drugs specifically target telomeric DNA
and to find their utility for other diseases.
This dissertation is organized in the following order: An introduction is given in
Chapter 1; an historical overview is given in Chapter 2; the theory, materials and methods
are given in Chapter 3; results and discussion are given in Chapter 4; mid Chapter 5 is
comprised of the conclusion and other possible future work, followed by references.

7
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CHAPTER II
HISTORICAL

DNA, is a nucleic acid that carries the genetic information in the cell and is
capable of self replication and synthesis o f RNA. It is composed o f a series o f monomer
units that are linked through covalent bonds. Each o f these monomer units, called
nucleotides, are made of a 2’-deoxyribose sugar connected with a phosphate group at its
5’-carbon and a purine or pyrimidine base at its 1’-carbon.41 The bond between two
successive nucleotides is through the phosphate group on the 5’-carbon o f one unit and
the hydroxyl group on 3’-carbon o f the next one, named the phosphodiester linkage. In
this manner, the construction o f long nucleic acid chains is established.

Figure 1

illustrates the chemical structure o f a small DNA polymer chain by displaying the
arrangements of the deoxyribose phosphate backbone and sugar molecules along with the
four major bases o f DNA.42
Watson and Crick were the first to propose the acceptable DNA structure in 1953
using X-ray diffraction fiber studies.43 Along with the X-ray diffraction data, earlier
chemical data obtained from other research groups helped to confirm the proposed
structure. According to their model, DNA is a two-stranded entity where the strands
interwine to form a right-handed double helix. The strands run anti-parallel to each other,
joined together through interstrand hydrogen bonds between purine and pyrimidine bases.
The base pairing is A-T and G-C in which adenine and thymine are bonded by two
hydrogen bonds and guanine and cytosine are bonded by three hydrogen bonds,
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respectively, as depicted in Figure 2. These matching base pairs can stack on one another
with their planes perpendicular to the helical axis.
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(center), and Hoogsteen base pairing for AT (right) [Blackburn and Gait, 1996],
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Studies o f DNA fibers using X-ray diffraction helped to elucidate two types o f
helices that configure into two different forms, A-DNA (Figure 3) and B-DNA (Figure
4). Both o f these conformations are oriented as right-handed helices, the A-DNA
conforms under the conditions o f low humidity while the B-DNA conforms under the
conditions o f high humidity.44 Figure 3 and 4 illustrates B-DNA with well-defined major
and minor grooves along its axis, where the A-DNA has both grooves of nearly equal in
depth. Although the majority o f DNA occurs in the B-form, others such RNA-RNA and
DNA-RNA helices exist in A-form 45
These structure conformation differences are influenced by the solvent
conditions at which the DNA or RNA resides. In aqueous solutions, there is extensive
hydrogen bonding between solvent water molecules and DNA. These are established by
the multiple hydrogen bond donor and acceptor sites present on sugars, phosphates and
bases. The phosphate group is a strong acid with a pK* o f about 1 while other residues in
a DNA molecule carry a negative charge at physiological pH.46
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Figure 3: A-DNA double helix [Mathews and van Holde, 1990]
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Figure 4: B-DNA double helix [Mathews and van Holde, 1990]

13

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

L

Telomere and Telomerase

Telomeres are the nucleic acid-protein complexes that occur at the end of
eukaryotic chromosomes. Telomeric DNA has been characterized to contain tandem
repeats of guanine rich or G-tract sequences such as d(TTGGGG) in tetrahymena,
d(TTTTGGGG) in Oxytricha, and d(TTAGGG) in Homosapiens.

It constitutes the

terminal lOkb of all human chromosomes.47'49 Telomeres’ functions are to maintain the
stability and integrity o f chromosome, preventing incomplete replication and end-to-end
fusions.50'53

Without the telomeric repair mechanism, the telomer length maintenance

will not suffice in preventing gradual loss o f genetic information since telomeres o f most
human cells shorten with each cell division due to incomplete replication o f linear DNA.
This limits the proliferative life span o f most human somatic cells to between 50-80 cell
divisions before they enter a state o f replicative senescence, termed as M l.54*55 On the
other hand, telomer lengths o f immortalized cells are constantly maintained and tightly
regulated by enzymatic mechanism o f telomerase, which specializes in reverse
transcriptase. The mechanism involves adding telomer repeats onto the pre-existing 3’
single stranded overhangs o f telomeric DNA Figure 5 demonstrates the mechanism of
how telomerase maintains the telomere length in eukaryotes.
Telomerase is a ribonucleoprotein complex that consists o f various subunits such
as the catalytic reverse transcriptase submit (hTERT)56, an RNA component (hTR)57, and
a number o f other associated protein subunits.58 Telomerase activity has been detected in
85-90% o f human tumors and tumor-derived cell lines, but is largely absent in most o f
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the human somatic cells.59 Many researchers have proposed that selective target o f
telomerase is an avenue for designing new anticancer drugs.60
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Figure 5: Mechanism by which telomerase adds short telomere segments to the 3’ end of
chromosomal DNA. These segments, which can then be primed, allow 5’> 3 ’
synthesis on the lagging strand.
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Research from the literature indicates the development o f chemotherapeutic
agents that are capable of providing selective inhibition of human telomerase for the
treatment o f cancer 61 The evolving knowledge on the composition, function and roles of
telomerase and telomeres in cell immortality and cancer has prompted the development
o f numerous distinct rationales for the development of various inhibitors.

Among

different strategies are antisense-based oligonucleotide inhibitors targeted against the
template region o f hTR, traditional reverse transcriptase inhibitors, and agents capable of
promoting and/or stabilizing high-order DNA quadruplex formation 62
The hTR transcript comprises approximately 450 nucleotides and contains an 11nucleotide sequence (5’-CUAACCCUAAC) template region complementary to the
human telomeric repeat sequence 5’ d(TTAGGG). The active functional part o f the RNA
is divided into two distinct domains. One o f the active domains consists the 3’ end that
functions as an alignment for binding o f the substrate, while the 5’ -domain acts as a
template for telomere elongation. The intrinsic accessibility o f the RNA template region
o f hTR offers an attractive target for enzyme inhibition compared to other antisensedirected mRNA targets due to its necessity for binding telomere ends.63
Since telomerase is a highly specialized DNA polymerase with reverse
transcriptase activity, its function is to synthesize telomeric repeats for attachment to the
3’ tail-end o f the telomeric DNA strand using an RNA template. It has been proposed
that the enzyme activity may be inhibited or prevented by chain terminating
dideoxynucleoside triphosphates (ddNTPs) and other nucleoside triphosphate reverse
transcriptase inhibitors.64
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There is considerable interest in the development o f highly selective and potent
small-molecule non-nucleoside inhibitors of telomerase. In this regard, several distinct
rationales have been explored. These include ligand-type agents, which are capable of
promoting the formation and/or stabilization o f high-order DNA quadruplex structures.
In addition, the effects of established anticancer agents on telomerase activity have been
examined in an attempt to determine if telomerase inhibition is a mechanistic component
o f drug efficacy.65
The observation of tandemly repeated segments of G-rich bases found in
telomeric DNA from most eukaryotes prompted the conclusion that telomeres must serve
some distinct biological roles.66 In addition, the discovery of DNA quadruplex formation
from such sequences has stimulated extensive development on the evaluation o f
quadruplex structure and function during the past decades.67 These structures are
believed to play a vital cellular role, despite their lack o f detection in vivo, and the
conservation o f telomeric DNA may be related to their inherent quadruplex formation.68
It has been established that RNA template region o f telomerase requires a linear unfolded
telomeric primer to affect telomere elongation; thus the presence o f telomeric quadruplex
structure leads to telomerase inhibition.69 As a result, DNA quadruplexes can be viable
targets for the development o f telomerase inhibitors. DNA quadruplexes inhibit the
enzymatic functions o f telomerase by preventing accessibility to the linear DNA
substrate. This functional cue has prompted many researchers to explore new ligands or
related agents that can selectively stabilize DNA quadruplexes and hence mimic K+ ions
as telomerase inhibitors.70
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II.

Polymorphic Nature of DNA

Most of the DNA in cells occurs as one of the three secondary structures random coil, B form, or A form.

But this does not extensively cover other

conformational possibilities for this extraordinary molecule. In recent years, several
other exotic structures have been observed and discovered by many researchers in various
scientific fields.

The types of DNA secondary structures were found to be very

dependent upon the DNA sequence as well as the solution conditions.71
One notable alternate structure o f DNA is Z-form, which is a left handed double
helix (Figure 6). The crystal structure o f Z-DNA was first characterized using X-ray
diffraction analysis to evaluate the oligomer with sequence d(CpGpCpGpCpG) 72 It has
been established that sequences with alternating dCdG are the most adept at forming ZDNA under high salt conditions. It has also been demonstrated that both B and Z forms
could exist in the same DNA molecule simultaneously, separated by a small junction ,73

18

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 6: Z-DNA double helix [Mathews and van Holde, 1990]
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Another alternate helical structure is triple-stranded DNA, first observed in
1957.74
The phenomenon was formed by the binding poly(dCT) to poly(dGA)#polyd(CT) and
poly(dG) to poly(dG)*polyd(C) by non-Watson-Crick base-pairing. The formation of
three stranded structures entails the binding o f oligonucleotides in the major groove of
B-form DNA by forming Hoogsteen or reversed Hoogsteen hydrogen bonds using the N7 o f the purine bases o f the Watson-Crick base-pairing (Figure 7). In theory, G can form
a base-triple with a G *C pair and A with a T*A but the only combinations that have
isomorphous location o f their C -l’ atoms are the two triplets TxA*T and C+xG *G (C+ is
the N-3 protonated form o f cytosine). This means that the three strands o f triple-helical
DNA are normally two homopyrimidines and one homopurine.75
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Figure 7: Formation o f DNA triplex from Non-Watson-Crick base-pairing for TAT (left),
TAA (center), and CGG (right) from Hoogsteen base pairing.
Other structures, such as cruciform DNA structures, have been shown to form
within supercoiled DNA in vitro76 and have been proposed to form in vivo.77 Holiday
junctions have been reported to form during the recombination o f two pieces o f double-
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stranded B-DNA in vivo.78 As mentioned earlier, three-stranded helical DNA has been
observed and studied79 Also, the existence of four-stranded DNA (e.g. quadruplex,
tetraplex, or G-tetrad) has been observed from sequences rich in guanine bases.

111.

DNA Quadruplexes

Guanine tetrads were first discovered in 1962 when Gellert et al. reported the
aggregation of guanine mononucleotide into gels.80 Gellert proposed that the formation
of a four-stranded structure was from the association o f the guanine bases into a quartet
structure through hydrogen bonding. This guanine-quartet structure is connected by
hydrogen bonding o f each guanine to two other guanines to form a closed ring with a
four-fold rotation axis, as depicted in Figure 8.81
Other researchers reported the formation o f Poly(G) into self-associated
complexes with extremely high thermal stability.82 The CD and IR spectra o f poly(G) are
veiy similar to those o f guanosine gels.83 This suggests that poly(G) might also be
forming a four-stranded structure. This hypothesis was later confirmed by two X-ray
fiber diffraction studies.84 Based on the detail evaluation of the diffraction patterns o f
poly (G), the formation of four-stranded helical structures was positively confirmed. It
was proposed that the guanines could be forming Hoogsteen type hydrogen bonding
similar to those found in G/G mismatches 85 From fiber diffraction studies o f poly-G
helices, they found that the four-stranded helical structure oriented with a 3.4 x 10'10 m
rise between hydrogen bonded guanine quartets as indicated in Figure 9.86
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Figure 8. Guanine-quartet (G-Tetrad) hydrogen-bonding array (R=H for guanine and
R=phospho-ribose for nucleic acids) [Gellert, 1962],
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Figure 9: Cyclic array of four guanine bases (a); Quadruple Helical Structure (b); G4 T4 G4
in Na+ solution determined by NMR (c); G4 T4 G4 in K+ solution determined by
X-ray Crystallography (d) [Williamson, 1994]

Furthermore, Sen and Gilbert also studied several oligomers containing G-rich
clusters corresponding to the immunoglobin G switch regions that constitute the sites for
recombination between the variable and the constant sequences during the differentiation
o f B lymphocytes to plasma cells.87 It was found that the Watson-Crick base-paired
DNAs form structures upon incubation in Tris-HCl buffer at 4°C, in which the Ccomplementary strands are looped out to form four-stranded DNA complexes (“M”
strands) composed o f base-paired guanine “quartets”. They referred to these complexes
as “G-4 DNA”. They extended these studies to assess the effects o f monovalent cations
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on the structures formed by telomeric DNA. 8 8 They observed that in the presence o f
Na+, the complexes contain four parallel strands and that the formation o f the complex is
a second order process. This suggests that the rate-limiting step in quadruplex formation
involves dimerization o f strands to form an intermediate duplex structure^). Increasing
K+ initially stimulates and then blocks the formation o f G-4 DNA. As the K+ is increased
above 50mM, their results show that intermolecular “fold-back” structures become
predominant. Sen and Gilbert proposed novel DNA superstructures formed by telomere
like oligomers. 8 9

They found that oligomer TgGjT forms a unique G4-DNA product at

neutral pH in the presence of Na+, K+, or Rb+; however its isomeric counterpart T9 G4 in
K+ or Rb+ generates an additional ladder o f products of substantially lower gel mobility.
They demonstrated that these larger complexes contain, respectively, 8 ,1 2 , or 16 distinct
strands of oligomers. Methylation protection experiments suggested a nested head-to-tail
superstructure containing two quadruplexes bonded front-to-back via G quartets formed
by out-of-register guanines. The results of this work are schematically shown in Figures
10

,

11

, and

12

.

In order to understand the stability of the G-tetrads, chemical probes have been
used extensively. The guanine base in a G-tetrad is nearly saturated with hydrogen
bonds, and hence is sensitive to small changes in the environment. DNA from Oxytricha
has determined to be resistant to both endo- and exonucleases. The N-7 o f the guanine
bases are involved in hydrogen bonding with neighboring bases and this affords stability
from compounds like dimethylsulfate. Dimethylsulfate can methylate the N-7 o f guanine
and cause depurination o f DNA. In fact, the stability o f the chromosomal telomerase is
due to the non-exposure o f N-7 o f guanine to external chemical agents. For example,
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several anticancer compounds such as cisplatin target the N-7 o f guanine in double
stranded DNA.90
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Figure 10. Schematic o f a back-to-back arrangement o f a G-8 DNA complex formed
from a G-4 DNA.

Other studies on the telomeric DNA complexes that contained 3’-d(T2G4)2
overhanging DNA showed that the molecules dimerize in a Na+ or K+ in a dependent
manner in which all N7 atoms o f the guanine bases o f the complexes are inaccessible to
DMS modification.91 The G-tetrad complexes are stable in buffers containing greater
than 100 mM KCL The authors also suggest that the thymidine residues may act as
“spacers” that serve with two function: (i) to reduce steric clash between the quadruplex
and adjacent duplex regions and (ii) to allow G-DNA hairpin formation by acting as
loops. This is consistent with the affinities o f the bases for water, since T is the most
hydrophilic and G the most hydrophobic of the DNA bases.92
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Figure 11. Schematic o f back-to-ffont (top) and back-to-back (bottom) models for G-8
DNA which involve bonding o f two G-4 DNA units via quartet formation by
slipped guanines from either unit. The un-bonded G’s are circled.

Figure 12. Schematics for G4-DNA formed by TnGj (A) and Tn-iQjT (B) and the
sugarcane type model of G8-DNA formed by T„G3 (C).

Recent studies have reported the architecture and stability o f these quadruplexes
to be highly dependent on DNA sequence as well as the conditions (e.g., buffer, ionic
strength, cations present, and temperature) under which the DNA is prepared. A number
26
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o f structural and thermodynamic studies on different G-DNA molecules have revealed
that cations induce and stabilize quadruplex formation in the order Cs+<Rb+<K+>Na+>Li+
for monovalent cations and K+>Ca2+>Mg2+ for divalent cations. This indicates that K+
has the optimal ionic radius for complex formation and stabilization. The effect of
different cations on the quadruplex stability is illustrated in Figure 13.
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U 10-

Figure 13. Plot o f the temperature at which 10% of the quadruplex population has
denatured (T0.im) versus the van der Waals radius of the corresponding
hydrated ions.

Williamson et al., studied the effects o f monovalent cations on DNA oligomers
corresponding to the four repeats of telomeric sequences o f Oxytricha and Tetrahymena
using non-denaturing gel electrophoresis experiments and DMS protection assay.93 They
found that these DNAs migrate faster than those o f the corresponding single-strands
under native conditions and that all N-7 positions o f guanine residues were resistant to
DMS modification in the presence of 50mM NaCl, KC1, and CsCl. UV cross-linking of
the thymine residues in the presence of Na+ is concentration independent, thus indicating
an intramolecular reaction. They concluded that the oligomers consisted of four repeats
o f telomeric sequences forming a compact, intramolecular folded back G-quartet
structure, in which the strands are pair-wise antiparallel and two o f the four guanines are
in a syn conformatioa They also noted that an arrangement o f the four guanines with
Hoogsten pairing is necessary to form G-quartet in a syn/anti/syn/anti alternating with
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respect to the glycosidic bonds (Figure 9). Such an arrangement allows for the alkali
cations K+, Na+, and Cs+, but not Li+, to form bonds with the four keto groups within the
central cavity.94
The molecular modeling on the interaction between quadruplex structures with
different mono-and divalent ions was determined by force field calculation in both
vacuum and solution. It was deduced that cations like K+ are tightly sandwiched between
both top and bottom neighboring planar o f the G-tetrad units build from the guanine
bases of the four DNA strands (Figure 14). The calculations in solution show that the
position o f water molecules in close proximity to the DNA channel has a strong influence
on the interaction potential, and hence on the capability of the cations for leaving and re
entering its potential sites.95 It was shown that van der Waals interactions at short
distances determine the specific characteristics o f the different cations.
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(C)

-H

Figure 14. (a) G-quartet with a model ion in the pocket, which is formed by four oxygen
06-atoms, (b) Potassium ion in the twisted cage formed by eight 06-atoms.
Wire frame presentations of the d[GGGG] 4 quadruplex structure, (c) View
perpendicular to the helical axis; (d) axial view. One ion is shown which is
trapped in the central cage.

Nuclear Magnetic Resonance (NMR) studies have also been used to characterize
detailed structural information about G-tetrads. Due to the repetitive nature of telomeric
sequences, the NMR analysis is spectrally overwhelming. Therefore, the assignment o f
resonance on the NMR spectrum becomes very difficult. These types of problems can be
reduced using two-fold or four-fold symmetric structures that simplify the NMR
spectrum for evaluation. The first detailed study on G-tetrads was done on G2 T4 G2 by
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revealing the glycosidic torsion angle alternated syn-anti for each adjacent pair o f G’s
along the strand 9 6
A more detailed study was later reported on the sequence G4 T4 G4 . In the
presence o f 50 mM Na+, a single predominant species is formed by this oligomer even at
4 mM DNA strand, concentration. Eight imino protons were observed, one for each of
the guanines, indicating that each guanine is involved in hydrogen bonding. As observed
for G2 T4 G2 the glycosidic torsion angles alternate syn-anti-syn-anti along the strand. 9 7
Investigations on telomeric DNA sequence dfl^G*) from Oxytricha through NMR
have also been reported in which a single copy o f the sequence produces an exceptionally
stable parallel stranded tetramer consisting o f four layers of G-quartets in an orderly
helical array.9 8
They proposed that all the G’s in this right handed helical quadruplex are in C2’
-endo, anti configuration and the T4 adjacent to the G-layer, shows the right handed
helical structure similar to that o f the G-tract and the rest o f the T-tract was more flexible
as shown in Figure 14.
The DNA aptamer d(GGTTGGTGTGGTTGG) has also been studied by NMR.
This particular DNA exhibits a highly compact and symmetrical structure, which consists
of two tetrads of guanosine base pairs and three loops. The residues o f the tetrads
alternate anti/syn/anti/syn as depicted in Figure 16."
In addition, early circular dichroism study on GtTxG4 oligomers indicate a four
stranded quadruplex when x = l,a quadruplex formed from the association o f two fold
back structures when x = 3 or 4 and a mixture of two possibilities when x = 2 .
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100

Recent NMR studies have shown that the preferred conformation for G4T4G4
consists of the two-stranded structure. The exact orientation o f the T4 loop is still under
debate. 101 Figure 15 displays some of the possible motifs generated from different DNA
oligomers.

'-llflV•’■£«a~7

(A)

(B)

Figure 15. (A) Energy minimized quadntplexed structure o f the sequence dT4 G4 . Eight
planes containing four G’s and four T’s. (B) Top view o f the stacking at the
T4-G5 steps. Each T stacks partially below two G-bases in the G5 layer, in an
interaction that seems to be stabilized by a K+ ion located between the planes.
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Figure 16. (top) A depiction of the tertiary structure of the aptamer is shown. The
dashed lines indicate the location o f the G-tetrads. (bottom) A depiction o f a
syn-anti-syn-anti tetrad is shown.
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Figure 17. Structure of parallel stranded quadruplex T4G4 (A), hairpin C4T4G4T4G4 (B)
and bimolecular quadruplex G4T2G4 (C).
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Figure 18. Schematic representation o f the bridging o f successive quaduplexes by two
strands, resulting in a linear superstructure with the individual tetrads and the
periodic “pockets”.
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Recent studies have demonstrated that certain G-rich sequences can selfassemble, under certain ionic conditions, to give rise to higher order structures.102
Studies from our laboratory showed that G-rich DNA such as C4 T4 G4 T 1-4 G4 and G4 T 1-4 G4
could form higher order structures as shown in Figure 18 studies, and gel electrophoresis
experiments suggested that these oligomers were unable to self-assemble under Na+, K+
or Mg++ alone, but would self-assemble into multistranded species o f high molecular
weight in the presence o f lOOmM K*plus 20mM Mg**. Since higher order structures are
not observed with K+ or Mg++ alone, these cations must behave in a synergistic manner in
order to stabilize the self-assembly o f supermolecular structures.
It has been reported that similar type o f self-assembly using G4 T2 G4 in the
presence o f 50mM Na+, or K+ as shown in Figure 16.104 The self-assembly process was
more efficient in the presence of Na+plus Mg++ or K*plus Mg++. The authors also came
up with similar structure as proposed by our group.105 They also studied the self
assembled “G-wires” through atomic force microscopy (AFM ).106'110
They found that the “G-wires” formed in the presence of Na+/Mg++ or KVMg^
were much longer than the ones formed under these cations alone (Figure 18). They also
observed that these quadruplexed DNA wires are more rigid as compared to the duplex
DNA. Thus the self-assembly o f oligomers possessing GtTxGj segments (where x = 1-4
or higher) generates a linear scaffolding with periodic spaced pockets (Figure 19).

35

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 19. AFM images o f self-assembling sequence d(G4 T2 G4 ) under different salt
conditions (Marsh, 1995],

In addition to electrostatic binding sites on the DNA backbone these periodic
“pockets” also possess hydrophobic and hydrogen binding sites, which are ideal
candidates for binding o f small ligands within these pockets. Ligand binding studies by
our laboratory have been evaluated to probe these types o f structures (Narayanan A.,
Ph.D. thesis, 1997).111
Currently work is being done by our laboratory to investigate the effects o f
sequence and environmental conditions on the self-assembly of these superstructures. By
understanding the properties and behavior of the self-assembly process, we may able to
engineer or “tune” these superstructures into relevant candidates for biological and
nanotechnological applications. Thus, specific designed DNA oligomers with sequences
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similar to the naturally occurring repeats mentioned above might provide a simplified
model for evaluating the structural and thermodynamic properties o f quadraplex DNA
formation.
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Figure 20. Schematic representation o f the pocket created in the self-assembly o f DNA
oligomers possessing G4T2G4.
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IV

The origin of Phthalocyanines

Phthalocyanine was accidentally discovered as bluish stable impurities in a reactor
made o f iron in 1928 that was used to manufacturer phthalimides. The word
"phthalocyanine" was made from Greek by Linstead in 1934.112
To date, phthalocyanine, metal phthalocyanine and metal phthalocyanine derivatives
have been manufactured in large quantities, and used as dye stuffs and pigments, because
o f their blue to green coloring and stability to visible light.
Molecular structures o f phthalocyanine, metal phthalocyanine and metal
phtalocyanine are similar to the naturally occurring porphyrins which were known to
make up vitamin Bn, chlorophyll and hemoglobin. Porphyrins are macrocyclic molecules
composed o f four pyrrole units, while phthalocyanines consist o f 4 isoindole units with
nitrogen

atoms

at

each

meso

position.

Phthalocyanines

are

also

called

tetrabenzoazaporphyrines or tetrabenzoporphyrazines.113
In this decade metal phthalocyanines and their derivatives are known for their use
in functional chromophores for electronics, sensors, biology and pharmaceuticals because
they possess a molecular structure similar to porphyrins which have exhibited high
electron transfer abilities owing to their %electron conjugated ring system.114
Phtalocyanines containing central metal atoms are called metal phtalocyanines.
Metal phtalocyanine have been prepared from every group in the Periodic Table.115
Pththalocyanines, metal phthalocyanines and metal phthalocyanine derivatives
can be synthesized by various methods. Phthalocyanine is synthesized directly from
diiminoisoindoline or phthalonitrile (1,2-dicyanobenzene) by cyclotetramerization.
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Phtalocyanine, metal phtalocyanine derivatives are also prepared from
diiminoisoindoline in the presence o f metal salts. In another major method, phthalonitrile
is used as a precursor in the presence of metal chloride. This method is called Linstead's
method or the Phthalonirile method.116
Another major route for the synthesis of phthalocyanines uses phthalic anhydride,
a metal salt, urea and a catalyst. This method is widely used in the manufacturing
process, and is called Wyler's method. Most metal phthalocyanines derivatives are
produced by the reaction between unmetallated phthalocyanine or lithium phthalocyanine
in the presence o f a metal salt.117

V.

Telomeres and cancer

Telomeres give our cells finite life spans. How is it that cancer cells seem to
possess infinite life spans? How can they reproduce and spread infinitely? How do cancer
cells get around the limits telomeres impose on our healthy cells and thereby become
immortal?118
In most organisms, including humans, the enzyme telomerase can add new
repeats of the TTAGGG sequence onto the tips o f telomeres to lengthen them. In most
non-human organisms, telomerase is always active when cells are dividing. This makes
up for the gradual telomere shortening from replication and cell division. This activity,
regulated by certain proteins, keeps telomere length more or less constant.119
Human cells are different. In most of them, telomerase is turned off. This means
telomeres shorten as cells continue to divide. However, almost 90% o f all cancer cells
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have been found to possess telomerase. Telomerase is an enzyme that "rewinds" our
mitotic or cellular clocks.120 Telomerase strengthens and lengthens our shortened
telomeres, replacing the bits of DNA lost in ordinary cell division. If telomerase stops
telomere shortening, then in theory, those cells with telomerase can live forever. Since
most cancer cells contain telomerase, researchers believe it is a critical factor in
conferring immortality upon these cells.121
Inactivation o f telomerase and the resulting telomere shortening likely evolved in
organisms to reduce the incidence o f cancer. By causing replicative senescence, telomere
shortening acts as a road block to the abnormally high amount of proliferation associated
with the development of cancer.122
However, telomere shortening itself may be an active contributor to the genetic
abnormalities that trigger cancer. There is growing evidence o f an association between
short telomeres and a greater risk o f cancer development in humans. In addition,
laboratory evidence has shown that short telomeres may contribute directly to the
progression o f the earliest stages o f certain cancers. In an experiment involving cells
taken from prostate cancer patients, researchers from the Johns Hopkins University
School o f Medicine found that telomeres in cells from precancerous lesions were four
times shorter than telomeres in cells taken from surrounding normal tissue.123 The
researchers believe that short telomeres contribute to cancer due to increased genomic
instability within cells with short telomeres.124
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VI.

DNA-Drug- interactions
Drugs are simply small molecules with biological activity. These can be used as

therapeutic agents in medicine, or also as tools in research laboratories. There are two
methods by which these small molecule drugs can interact with the DNA double helix.
They can bind in the grooves or alternatively, they can stack in between the base pairs
within the helix (called "intercalating").125

i. Intercalating Drugs
This group o f drugs tend to be planar molecules, primarily aromatic rings. This is
necessary, first for the steric features o f the double helix, and also for the hydrophobic
quality o f the nitrogenous bases. These drugs cause drastic local changes in the geometry
o f the DNA where it interacts. If there had previously been any supercoiling, this would
be disrupted by the drug. An example used to demonstratethis theory is Actinomycin D.
This small molecule binds between C-G and G-C base pairs. It inhibits replication o f the
genome and transcription o f genes, by preventing the separation o f the DNA strands. This
drug was developed in Auckland and is a therapeutic treatment for leukemia.126
In the early 1960, Lerman described a number of physical studies on the
interactions o f DNA with planar aromatic cations.127 He concluded from these studies
that planar aromatic molecules could bind to DNA. He proposed a mechanism where the
aromatic molecules could slip in between the base pairs o f DNA, a process that he termed
as intercalation (Figure 20). This classical model has now been established for a large
number o f polycyclic aromatic compounds. As a result of rotation about torsional bonds
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in the DNA backbone, the creation of an intercalation site causes separation o f base-pairs
and a lengthening of the double helix which can be detected by hydrodynamic methods,
such as viscosity and sedimentation. Groove binding molecules do not significantly
increase the viscosity o f sonicated DNA or unwind DNA base pairs.128 In the classical
model, the helix is lengthened by 3.4 x 10'10 m maximum as a result of intercalation. The
helix is unwound at the site of intercalation complex and the normal approximately 36°
rotation o f one base pair with respect to the next is decreased as a result o f intercalation.
The amount o f unwinding depends upon the structure of intercalating molecules and
probably on the DNA sequence in a manner that is not very well understood. The
anthracycline drugs duanomycin and adriamycin unwind DNA by 11°, ethidium and
propidium give unwinding angles o f 26°, and proflavine and related acridines unwind
DNA by 17° per bound molecule.129
Crystallographic studies provide molecular detail concerning intercalators
induced tilt and long-range compensating effects in the DNA duplex. In general, drugs
such as proflavine and ethidium are stacked with their long axes parallel to the long axes
of the adjacent base pairs in these crystal structures. The exocyclic amino groups o f the
intercalators point towards diester oxygens of the DNA phosphate groups at the
intercalation site and provide additional eletrostatic and hydrogen bonding stabilization of
the complex. The base-pair centers are separated by 6.9 angstroms in the complex and
stack well with the intercalated system.130
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Figure 21: Sketch of B-DNA (left) and Drug-DNA complex (right).

Wang and coworkers obtained the first crystal structure with a monointercalator
and oligonucleotide o f the antibiotic daunomycin and the oligomer d(CGTACG).131
Daunomycin binds to the duplex with its long axis almost perpendicular to the long axis
o f adjacent base-pairs at the intercalation site (Figure 21). The daunomycin amino-sugar,
which is attached to ring A of the anthracycline ring system, lies in the minor groove
while ring D, which bears a methoxy group, protrudes into the major groove. The
daunomycin core, rings B and C, lies between base-pairs. The DNA has two daunomycin
molecules at each CG unit present at the two ends. The AT base-pairs retain a general BDNA like geometry in the complex, but with some backbone distortions.131 As expected,
the C:G intercalation site opens by 3.4 A to create the intercalation space. The cationic
amino-sugar substituent and ring, largely fill the minor groove and displace water
molecules and ions from it. Ring A has a hydroxyl group that can form a hydrogen bond
with the N-3 o f guanine and can accept a hydrogen bond from the amino group o f the
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same guanine. This results in favorable binding energy and orientational specificity for
the intercalated drug.132
The conformation o f the duplex is also changed significantly relative to the BDNA helical structure to accommodate the antibiotic.

In addition to the increased

separation o f base-pairs at the intercalation site, the G-C base-pairs are also shifted
laterally towards the major groove so that the helix axis changes position. At the
intercalation site, the base-pairs maintain the usual 36° helical twist, but base-pairs at
adjacent sites are unwound by 8°.133

o

OH

o

Figure 22: Examples o f classical intercalators: Daunomycin, R=H; Adriamycin, R=OH
(left) and Ethidium bromide (right).

Most intercalators display either no binding preference or a slight G:C base-pair
preference and this contrasts with the general A:T preference o f outside binding
compounds. It has been suggested that the general G:C preference o f intercalators is due
to the larger intrinsic dipole moment o f G:C relative to A:T base-pairs and the resulting
ability of G:C base-pairs to induce polarization into the ring system of intercalators.
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Nonetheless, intercalators with an A:T preference have been synthesized.134 This shows
that overall binding specificity must depend not only on dipole interactions with
polarizable intercalators but also on hydrogen-bonding interactions, and the size,
hydration, and electrostatic potential of the grooves and other similar factors.
If the groove binding molecules and intercalators are compared, it is clear that
groove-binders, as a class, display significantly greater binding selectivity than
intercalators. Intercalation cavities created at A:T or G:C base-pairs are quite similar in
their potential for interaction with planar aromatic ring systems. Electrostatic, van der
Waals, hydrophobic, etc. contributions to binding are similar for the two sites. On the
other hand, groove-binding molecules can contact more base-pairs as they lie along the
groove in a

DNA complex and this give them an inherently greater recognition

potential.135
Simple intercalators with reduced steric constraints such as proflavine and
ethidium bromide could potentially intercalate at every base pair site. Saturation o f the
double helix and intercalators would yield a binding stoichiometry o f one base-pair per
bound intercalator. While models o f duplex DNA with reasonable backbone torsional
angles can indeed be constructed with intercalators at all possible sites between basepairs, solution studies indicate that even the simplest intercalators reach saturation at a
maximum o f one intercalator per two base-pairs.136 The neighbor exclusion principle
states that intercalators can bind at alternative possible base-pair sites on DNA, giving a
maximum o f one intercalator between every second site. Initially, all spaces between
base-pairs are potential binding sites for a non-specific intercalator. When an intercalator
binds at one particular site, the exclusion principle states that it becomes impossible to
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bind another intercalator at either adjacent site. One suggestion for the molecular basis o f
neighbor exclusion is that intercalative binding induces conformational changes at
adjacent sites in DNA and the new conformation makes it impossible to intercalate
another monointercalator at the adjacent site.
At alternative theory was proposed by Friedman and Manning.137 According to
them, for long pieces o f DNA, as the intercalators bind to DNA, they neutralize some of
its charge. This leads to a lower apparent binding constant since the favorable release o f
condensed ions is reduced, giving rise to a curvature in binding isotherms, similar to that
predicted by neighbor exclusion. Since the local release o f ions due to intercalation would
be greater than ion release at a distance along the DNA molecule, the local release of
counterions could also lead to reduced binding at neighboring sites. It is likely that both
conformational as well as electrostatic forces contribute to the observed neighbor
exclusion.138
Non-classical Intercalators: Intercalators which have substituents on opposite
sides of the ring system and must thread one o f the substituents between the base-pairs at
the intercalation site in the binding mechanism. If the substituent is bulky and/or polar or
charged, this could be an unfavorable step, which might profoundly affect the kinetics of
association and dissociation o f the intercalator. Examples o f such type o f intercalators
are naphthalene-bisimides cationic porphyrins.139
The binding mechanism o f simple intercalators such as proflavine involves two
steps. First, the cationic intercalator interacts with DNA through an external electrostatic
complex with the anionic backbone o f the double helix. The intercalator then can diffuse
into the anionic potential along the surface o f the helix until it encounters the gaps
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between base-pairs which have separated as a result o f thermal motion to create a cavity
for intercalation. The molecule can then bind in an intercalation complex.140
These types o f molecules all have very high DNA binding constants, indicating,
that once the side chain slides between the base pairs, the DNA molecule can assume a
conformation that gives a very favorable free energy of complex formation. The side
chains present a kinetic barrier to binding but have favorable interactions in the final
complex after they have passed through the double helix. The kinetic barrier o f binding
depends on the size o f the side chain, its orientation, and its polarity.141
Porphyrins are particularly interesting compounds since they appear to intercalate
in G:C rich regions of DNA, but bind in the minor groove at A:T rich regions. Their
binding properties vary substantially with the cationic substituent and type o f the metal
bound centrally in the porphyrin. Oligonucleotide NMR studies by Marzilli, Wilson and
coworkers have suggested that the intercalating porphyrins have very high selectivity for
binding a CpG sequence.142 This is unusual since the porphyrins do not have the
hydrogen-bonding capability observed for other molecules that show high selectivity for
binding at specific DNA sequences.

ii. Groove-Binding Drugs

Medicinally, these are primarily molecular "blocking" devices. They prevent the
binding o f other proteins and enzymes to the area o f DNA where they are bound to. In
this case, the example used is Netropsin, which interacts specifically to B-DNA, but not
A- or Z-DNA. It binds in the minor groove, displacing water molecules, and is a perfect
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fit in A-T rich regions. It also prevents replication and transcription, by blocking the
binding of polymerases to the DNA. It occupies approximately 6 base pairs along the
helix.143
The major and minor grooves differ significantly in electrostatic potential,
hydrogen-bonding characteristics, steric effects and hydration. Most o f the proteins and
oligonucleotide molecules are specific towards the major groove while small groove
binding molecules in general prefer the minor groove. Netropsin and distamycin are
typical minor groove binders.144
Typically, minor groove binding molecules have several simple aromatic rings
such as pyrrole, furan, or benzene connected by bonds with torsional freedom. The
minor groove is generally not as wide as A:T-rich relative to G:C-rich regions and may
'fit' aromatic molecules better at A:T than G:C sequences. A molecule, given the correct
twist of its linked aromatic rings, can fit snugly into the minor groove and form van der
Waals contacts with the helical chains o f the groove.145 There is the possibility for
hydrogen bonding between the bound molecule and A:T base-pairs at C-2 carbonyl
oxygen o f T and the N-3 nitrogen o f A. Although similar groups are present at G:C basepairs, the amino group o f the G presents a steric block to hydrogen bond formation at N-3
o f G and at the C-2 carbonyl o f C. The hydrogen bond between the amino group of G
and the carbonyl oxygen o f C in G:C base-pairs lies in the minor groove and sterically
inhibits the molecules from penetrating into this groove in G:C rich regions.146 Thus the
aromatic rings of many groove binding molecules form close contacts with the H-2 o f A
in the minor groove o f DNA. It has also been shown that the negative electrostatic

48

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

potential is greater in the A:T minor groove than in the G:C rich regions o f DNA and this
provides additional important source for A:T specific minor groove binding of cations.196
A possibility with groove binding molecules that does not exist with intercalators
is that they can be extended to fit over many base-pairs along the groove and have high
sequence specific recognition o f nucleic acids. For example, an oligopyrimidine can be
designed which forms a triple helix with a specific homopurine-homopyrimidine duplex
sequence. By linking DNA cleavage reagents to the oligopyrimidine, a highly specific
'nuclease' can be created.147

iii. Electrostatic interactions

Condensation type interactions: These interactions usually involve the binding along
the exterior o f the helix through interactions that are generally non-specific. Manning et
al. have shown that B-DNA is considered as a line o f equally spaced charges, with one
anionic charge per 1.7 angstrom. If the line charge spacing becomes less than
approximately 7 angstrom, the molecule becomes unstable and associates with cations
such as Na+’ K+ from solution to achieve stability.148 The association o f ions with the
polyelectrolyte is called counterion condensation and causes an unfavorable entropy term
in the overall polymer conformational free energy summation. This unfavorable term is
overcome by various other favorable interactions in the DNA double helix. Counterions
'condense' until the charge density is reduced to the stable level o f approximately one
charge per 7 angstroms.

Additional counterions are associated with the remaining

charges on the polyanion through Debye-Huckle type interactions.149 For a specific
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nucleic acid conformation, the charge density and thus the amount o f condensed
counterion is constant.

The initial association o f counterions is referred to as

condensation, since the ions are associated with the general charge density o f the
polyelectrolyte and are not bound at specific sites. The ions retain their inner sphere
water of hydration and move rapidly along the sugar-phosphate backbone of DNA.150
Secondary hydration layers o f both the polyelectrolyte and counterion are affected by this
interaction.
Outside Stacking: Planar aromatic molecules can stack on each other to form
dimers and higher aggregates. When compounds are charged, such as proflavine and
porphyrins, they repel each other electrostatically.151 If, however, cations stack along the
anionic DNA sugar-phosphate chain, the charge repulsion is decreased and this type o f
binding leads to nonspecific outside stacking o f planar cations along the double helix. A
large fraction o f condensed counterions are released when such stacking takes place. It is
therefore highly dependent on salt concentration and is generally quite weak at salt
concentration o f 0.1 M and above. Because this binding mode is a type o f extended self
association, it can be highly cooperative and will generally be more favorable at high
ratios of aromatic cation to DNA phosphate.152

VII.

Porphyrins and DNA

The first evidence that porphyrins are capable o f intercalating into DNA came in
1979 by Fiel et al. reporting that the tetracationic meso-substituted porphyrin, 5,10, 15,
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20-tetrakis(4-N-methylpyridyl)-porphine (TMPyP4) can intercalate into calf thymus
DNA (Figure 22).153
This result was received with some surprise and even skepticism given the
structural features o f this molecule: X-ray crystal structures show the plane o f Nmethylpyridyl group to be at a 66-72° angle with respect to the main porphyrine core and
NMR studies indicate that the rotational barrier for these N-methylpyridyl groups to
obtain coplanarity with the porphyrine core is relatively large.154
Thus, considerable steric constraints appear to exist for passage o f these
molecules between the base-pairs o f DNA helix to form an intercalated complex. Since
the original report indicating porphyrin intercalation appeared, a number of studies
utilizing a wide range o f techniques have been conducted and a detailed picture of the
mode(s) and mechanism(s) of this binding process has emerged.155
Pasternack and his group have studied in great detail the interactions o f TMPyP4
and their metal derivatives with synthetic DNA. Their work is primarily responsible for
the use o f porphyrins and their metal counterparts as probes for studying drug-DNA
interactions. On the basis o f visible absorption spectroscopy, circular dichroism
spectroscopy and kinetic studies, they suggested that TMPyP4 and its metal derivatives
without the axial ligands[Au(m), Cu(II), NiQI)] are capable of interclation when
interacting with poly(dG-dC)2 . 156

It was reported that the intercalation process was

accompanied by large bathochromic shift and substantial hypochromicity o f the Soret
band, a negative induced CD band in the Soret region o f the porphyrin chromophore and
binding kinetics that can be measured by temperature jump relaxation techniques. These
same non-axially liganded porphyrins were shown to bind externally to poly(dA-dT).
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The externally bound complexes displayed moderate bathochromic shifts and
hypochromicity (in some cases a hyperchromicity) and a positive induced CD band in the
Soret region of the porphyrin chromophore.157
Mn(HI) porphyrins were shown not to intercalate into either poly(dG-dC) 2 or
poly(dA-dT)2 but bind externally to both polymers. It was suggested that the inability o f
these metalloporphyrins to intercalate was probably due to the additional steric
requirements imposed by their axial ligands. Carlin, and coworkers considered binding
patterns for the positional isomers o f TMPyP4 at conditions similar to those of the above
studies, importantly at low drug load (i.e f> =[porphyrin]o/[DNA]0 is small).158
Based upon unwinding studies of covalently closed supercoiled DNA (ccs
DNA), the 3-N methyl isomer metalloporphyrins with axial ligands [Zn(II), Co(III),
Fe(III), and TMPyP3 were shown to be intercalators. However, TMPyP2, in which the
N-methyl group is in the ortho position (Figure 22), and H2TAP (meso-tetrakis(N2N2Ntrimethyl anilinium)porphine), another cationic porphyrin, do not unwind ccs DNA which
is typical for non-intercalators.159 As would be predicted for external with Poly(dG-dC)2
(at low r0) both display positive induced CD bands.

All three sppcies (TMPyP3,

TMPyP2, H2TAP exhibit positive induced CD bands with poly (dA-dT)2 as does
TMPyP4, again indicative o f external groove binding. Therefore, the binding mode
preferences o f cationic meso substituted porphyrins can be modulated not only by
changes in the coordinated metal but also by alterations in the porphyrin periphery.160
It has also been shown that, for the interaction o f TMPyP4 with calf thymus
DNA, at low values o f drug load (rQ =[drug]/[DNA] = 0.1), the mode o f binding is
intercalative at low ionic strength and external at high ionic strength.161 At higher drug
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loads (ro>0.2), the binding of TMPyP4, TMPyP2, and H2 TAP to DNA becomes more
complex and the resultant CD spectra become more complicated. These effects are due
to the conformational changes of the polymers, stacking o f externally bound molecules
on the surface of the DNA, aggregation of the polymers, and unavailability o f more sites
as a result of intercalative sites leading to outside binding.162
Marzilli and coworkers have studied the binding of TMPyP4 with poly(dG-dC) and poly
(dA-dT) by equilibrium dialysis and stopped-flow dissociation kinetics as a function of
the concentration of Na+. Rates o f dissociation from poly (dA-dT) were similar for
TMPyP4, ZnTMPyP4 and NiTMPyP4, which have similar mode o f binding.

The

TMPyP4 and NiTMPyP4 dissociation rates from poly(dG-dC) were measurable while the
dissociation of ZnTMPyP4 was too fast to measure (outside binder). Increasing the [Na+]
from 0.115 M to 0.515 at 20°C increased the fast and slow dissociation rate constants by
a factor o f 204 for TMPyP4 dissociation from poly (dG-dC) indicating an intercalative
mode o f binding.163 DNase was used to study the foot printing of different porphyrinDNA complexes.164 DNase digestion produces a larger degree o f cutting at the GC sites
and small edges o f cutting at the AT sites. The lesser degree o f cleavage of AT sites is
indicative of externally bound porphyrin, which protect the AT sites from cleavage.
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Figure 23: Structures o f different pophyrins and their metal derivatives.
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Conversely, intercalated porphyrins in the GC sites afford no protection for the
DNA against DNase

that is seen as larger amount of cleavage products in the

footprinting assay.165
As found with other intercalating drugs, porphyrins and metalloporphyrins are
capable o f converting Z-form DNA to the right handed B conformation. Kinetic studies
imply that these porphyrin species intercalate into Z-form prior to B formation although
some uncertainly exists as to the nature o f drug-Z-DNA complex. It has been suggested
that conversation o f DNA between Z and B forms could be one mechanism for control of
geiletic process.166 If this is the case then these intercalating porphyrins could interfere
with such control mechanisms by binding to Z-regions o f DNA and converting them to
the B-form or by preventing conversation o f B-DNA to the Z conformation in vivo.
Aggregation studies on the effects of meso-substituted porphyrins by light
scattering techniques have been done.167 Addition of NaCl to aqueous solutions o f tH 2 Pagg or t-CuHaPagg [{trans-cis(n-methylpyridinium-4-yl)}diphenylporphyrine and its
Cu(H) derivative], initially at an ionic strength o f zero, leads to a large bathochromic shift
and hypochroism o f the Soret band indicating extensive aggregation o f these porphyrins.
Extensive scattering was observed for t-HaPagg with the scattering profile showing a
wavelength dependence characteristic o f the spectrum of the scattering species with an
absorption maximum at 455 nm.168 The extent o f the scattering is dependent on the ionic
strength in a manner to be expected for a self-aggregation process involving charged
species. The most dramatic effect arising from the complexation to nucleic acids by the
t-HaPagg and t-CuHaPagg porphyrin derivatives under 0.1 M NaCl is the generation of
circular dichroism signals 1-2 orders o f magnitude larger than those observed under low
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salt conditions. Patemack suggested that unaggregated DNA could serve as a template
on which t-tfePagg and t-CuH2Pagg form long-range chiral assemblies.218
CuTMPyP is the square planar complex o f TMPyP4 and has no axial ligands.
The porphyrin intercalates between the C and the G of 5' TCG 3' and exludes the C o f the
5'CGA 3'.

Only four normal

Watson Crick base pairs are observed in the DNA

porphyrin complex.169 In addition, the DNA forms a distorted right-handed helix.
Electrostatic interactions between positively charged nitrogen atoms of the porphyrin and
the oxygen atoms of the phosphate backbone of the DNA seemed to extensively stabilize
the DNA-porphyrin complex. These favorable interactions offset the unfavorable steric
clashes between the pyridine rings o f the porphyrin and DNA backbone. The pyridine
backbone clashes elongate the DNA along its axis, which reduces the stacking
interactions in the interior o f the DNA-porphyrin complex that was observed as decreased
energetic cost o f local melting.170

VIII.

Porphyrins and DNA quadruplexes

The development of agents for the structure specific recognition o f DNA
quadruplexes has largely stemmed from experience with intercalators for duplex or
triplex DNA. Most o f these compounds are based upon planar-extended aromatic ligands
where DNA binding is anticipated via molecular ^-overlap with the G-tetrad planes.
Qualitative support for this approach was provided by a report that the dye ethidium
bromide binds to intermolecular quadruplexes by a mode consistent with intercalation.171
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The cationic tetra-(N-methy-4-pyridyI)porphyrine has recently been shown to
bind to quadruplex-form DNA and inhibit telomerase activity. A wide range o f related
porphyrin derivatives have since been examined, providing a basis for early structure activity relationships.

However, while it is established that these agents bind to

quadruplex DNA and that this binding must be implicated in the telomerase inhibition,
the mode(s) of binding are by no means unambiguous.172 The stoichiometries, affinities
and sites for binding remain controversial, with alternative intercalated, end-pasted or
sandwich-type interaction modes. While the mechanism of binding is still unclear, it is
already known that the binding behavior is also influenced by the solution conditions and
the DNA complexation. In addition, caution should be taken in comparing binding
properties from alternative and dissimilar assay methods.173
Studies o f the interaction of TMPyP4 with the parallel quadruplex formed by T4 G4 ,
and with the duplex formed by d(CGCGATATCGCG) have been condicted by Sheardy
and coworkers.174 Results from visible absorption spectroscopy, circular dichroism, and
fluorescence energy transfer experiments showed that TMPyP4 binds to both the duplex
and quadruplex with high affinity. While this particular porphyrin was shown to bind to
duplex DNA via intercalation, the mode o f binding for quadruplex DNA was suggested
to be both intercalative as well as end pasting forming a "sandwich" type complex
involving one porphrin stacked between the 5' termini G tetrads o f two quadruplexes.
The interaction between porphyrin with three quadruplexes has been studied using
calorimetry, molecular modeling and spectrophotometry. These studies showed that the
binding affinity is rather weak and that the binding stoichiometry corresponds exactly to
the number o f intervals between stacked G-tetrads in each DNA structure (e.g., the
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human d[AGGG(TTAGGG)3 ] quadruplex with three G-tetrads planes will bind two
porphyrins. According to the thermodynamic parameters obtained, they suggested the
binding mode to be intercalative rather than end-pasted or sandwich type binding.175
Bolton and his coworkers studied the interaction of anionic N-methyl
mesoporphyrin NMM, and some other porphyrins with different DNA quadruplexes
including aptamer. Their fluorescence energy transfer experiments suggest that the
porphyrin NMM favors the binding to quadruplex DNA rather than duplex form DNA
and so could offer a route to the specific detection of quadruplex DNA under biologically
important conditions. In other studies done by NMR, they have shown that at high DNA
concentrations, certain porphyrins catalyze the conversion of both chair and basket type
structures into parallel strand quadruplex DNA.176
It has also been shown that the fluorescence o f selected porphyrins can be used to
discriminate between duplex and quadruplex DNA as well as between different
secondary structures of DNA quadruplexes.177
In another study done by Hurley and coworkers, interactions o f TMPyP4 and
TMPyP2 with an antiparallel quadruplex DNA were studied. Both o f these cationic
porphyrins posses similar structures but have been shown to have strikingly different
potencies for telomerase inhibition.

A single stranded DNA oligonucleotide (G4A)

containing four human telomere repeats of GGGTTA was designated to form an
intramolecular quadruplex structure. Thermal melting profiles show that both TMPyP4
and TMPyP2 stabilize quadruplex DNA to about the same extent. The photocleavage
assay shows that TMPyP4 binds by stacking externally to the guanine tetrad at the GT
step, while TMPyP2 binds predominantly to the same G4A DNA structure via external
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binding to the TTA loop and this difference in binding locations accounts for differential
effects on telomerase inhibition by both porphyrins.178
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CHAPTER III
THEORY, METHODS AND MATERIALS

I:

Theory

The recognition o f DNA at a molecular level is one the most important
discoveries o f science. The ability to study the interaction o f small molecules with DNA
and being able to understand how these ligands bind to DNA is the key to designing new
novel molecules for the treatment o f deseases. Research in the past 20 years has been
focused on the type of binding between DNA and small molecules. Also, the thrust has
been focused on the main types o f noncovalent small DNA interactions as it pertains to
intercalation, groove binding and simple electrostatic interactions.179
The discovery that simple tandemly-repeated G-rich telomeric DNA is preserved
in most eukaryotes and that these repeats can fold into four-stranded quadruplex
structures, spurred a growth in research in this area which has created a greater
understanding and has stimulated new discoveries during the past 20 years. Quadruplexes
are believed to play a vital cellular role, despite their lack o f detection in vivo, and the
preservation o f telomeric DNA sequences may be related to their inherent quadruplex
formation.180 This hypothesis is supported by recent findings that many telomeric DNA
binding proteins bind to quadruplexes and or promote their formation and may also
regulate telomerase activity. Moreover, it is now established that the RNA template
region of telomerase requires a linear unfolded telomeric DNA primer to effect telomere
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elongation. Consequently, the presence of a telomeric quadruplex structure leads to the
inhibition o f telomerase activity. Such an identification of DNA quadruplexes as a target
for the development of telomerase inhibitors has aroused the recent search for new
ligands that can selectively stabilize DNA quadruplexes and hence eventually could be
used to inhibit the activity o f telomerase.181 The key step towards such formulations,
however, is to have a better understanding o f the structure and conformation o f these
DNA quadruplex systems, which are extremely sensitive to the sequence o f DNA as well
as the environmental conditions. In addition, stoichiometries, binding affinities, and the
mode o f binding o f ligands to these quadruplexes are the questions to be addressed in
order to Optimize the efficacy o f such agents and to prevent their unwanted depletion by
competitor DNA target sites.
The purpose o f this study was to synthesize porphyrazines and to study the
binding of different porphyrazines to DNA quadruplexes, DNA duplexes and DNA single
strands. The present study used atomic force microscopy, competitive dialysis and uv/vis
spectroscopy to investigate if specific porphyrazines would interact with certain DNA
quadruplexes, DNA Duplexes and DNA single stranded oligonucleotides and to see if the
porphyrazines have any utility as potential AIDS and cancer inhibitors. The essence o f
his work is to expand the utility o f porphyrazines as potential cancer and AIDS
pharmaceutical agents and to expand the current database with respect to DNA
quadruplexes and to understand how porphyrazines can stabilize DNA.
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DNA Synthesis

Each self-complementary DNA strand was synthesized by the automated
phosphoramidite method o f the Applied Biosystems 380B DNA synthesizer (Foster City,
CA).

The synthesis is done with the growing nucleotide chain attached to a solid

Controlled Pore Glass (CPG) support so that excess reagents that are in a liquid phase can
be removed by filtration. As the starting material, the solid support is derivatized with the
nucleoside that will be the 3-hydroxyl end o f the product. The nucleoside is bound to the
silica solid support through a long spacer arm attached at the 3'-hydroxyl via an ester
bond, which is base labile and allows for removal of the DNA from the support. All free
silanol groups are capped to prevent side reactions. The 5'-hydroxyl is blocked with a
dimethoxytrityl group. Thus, automated DNA synthesis builds the oligonucleotide chain
3' to 5'. The use of the solid support is essential to the automation of DNA synthesis
because it eliminates the need for purification steps between base additions.
The first step o f the synthesis cycle is treatment of the derivatized solid support
with acid to remove the trityl group and free the 5-hydroxyl for the addition reaction.
The next step, activation, creates a highly reactive nucleoside derivative that reacts with
the hydroxyl group.

The intermediate is created by simultaneously adding the

phosphoramidite derivative of the next nucleoside and a weak acid, tetrazole, to the
reaction chamber. The tetrazole protonates the nitrogen o f the phosphoramidite, making
it susceptible to nucleophilic attack. Since this intermediate is so reactive, the addition
reaction is complete in less than 30 seconds at room temperature.

The added

phosphoramidite is blocked at the 5'-hydroxyl end with the dimethoxytrityl group. The
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exocyclic amines on adenosine (A) and cytosine (C) are protected by a benzoyl group and
the exocyclic amine on guanosine (G) by an isobutyryl group. Thymidine is already
unreactive and does not need a protecting group.
The next step, capping, terminates any chains that did not undergo addition. Since
the unreacted chains have a free 5'-hydroxyl, they can be terminated or capped by
acetylation.

This reaction is accomplished with acetic anhydride and dimethyl-

aminopyridine. Since the chains that reacted with the phosphoramidite in the previous
step are still blocked with the dimethoxytrityl group, they are not affected by this step.
Although capping is not required for DNA synthesis, it minimizes the lengths o f the
impurities and thus facilitates the purification by Reverse Phase-HPLC.
The intemucleotide linkage is then converted from the phosphite to the more
stable phosphate. Iodine is used as the oxidizing agent and water as the oxygen donor.
This reaction is completed in less than 30 seconds. After the oxidation step, the
dimethoxytrityl group is removed by acid hydrolysis, and the cycle is repeated until chain
elongation is complete. At this point, the oligonucleotide is still bound to the support and
has protecting groups on the phosphates and the exocyclic amines o f the bases A, G, and
C. The chain in then cleaved from the support by a one-hour treatment with concentrated
ammonium hydroxide. After the solution containing the DNA is removed from the
instrument, the protecting groups on the exocyclic amines o f the bases are cleaved by an
18-hour treatment with concentrated ammonium hydroxide at 55 °C.
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Porphyrazines and General methods of preparation

The synthesis o f porphyrazine derivatives are of great interest due to their
applications in liquid crystals, chemical sensors, and nonlinear optics.182 The emerging
field of photodynamic cancer therapy has also prompted interest in porphyrazine
derivatives as potential target molecules for treating cancer.183
Cationic porphyrins and porphyrazines, metallated and nonmetallated, have also
attracted much attention as photosensitizers for photodynamic cancer therapy based on
their DNA binding properties.184 The porphyrin ring sytem has been one o f the most
studied macrocyclic ring systems. Research in this naturally occurring tetrapyrrolic
macrocycle is based and derives in part from its biological functions as well as its ability
to be an excellent metal-complexing ligand.185 This chemical has opened the study o f a
range of porphyrin analogues. The thrust in research devoted to these latter systems is
based on their resemblance to porphyrins and the vision that they will show a rich
coordination chemistry that parallels that of the porphyrins. Also, the electronic structure
o f various larger porphyrin systems, in particular their resemblance and differences to
10A

porphyrins, have made them an area of intense study.
The uv-vis study o f conjugated expanded porphyrins display absorbance bands that
are considerably red-shifted relative to those of porphyrin, and this unique chemical
property makes them perfect candidates as photodynamic theurapeutic agents.187
In recent years, unsubstituted and symmetrically substituted phthalocyanines,
tetrabenzoporphyrazines, naphthalocyanines have been researched as second
generation photosensitizers due to increased p-conjugation, this has led to the theory
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that certain expanded porphyrins could find use as therapeutics for photodynamic
therapy.188 The properties, including ease of reduction, has resulted in the testing of
one particular expanded porphyrin (xcytrin; motexafin gadolinium) as an adjuvant for
X-ray radiation therapy. Another area of interest in the porphyrin field has been
focused around the discovery that expanded porphyrins can act as anion receptors.189
These findings have made these systems a potential area of interest for use in a
variety of applications, including anion sensing and transport for drug delivery, as
well as chromatography-based purification of anions.190
Metallated or unmetallated phthalocyanines, are referred to as phthalocyanine (pc),
are usually prepared from phthalonitrile or from l,3diiminoisoindoline. Twigg and
coworkers heated phthalonitrile in methylnaphthalene or other high boiling solvents in
the presence of catalytic amounts of cyclohexylamine.191 Other amines such as
lanthanum chloride triethylamminate has been used. Heating phthalonitrile in dioxane
at 200 °C under hydrogen pressure gives moderate yields. Tetraphenyl-pc is also
prepared by refluxing 4-phenylphthalonitrile, with a catalytic amount o f ammonium
molybdate, and isoamyl alcohol containing sodium for 5 hours. After filtration the
product is stirred with ethanol for 10 hours, filtered and dried.192 Naphthalocyanine is
made in the same manner and then is converted to many different metal
phthalocyanines. Reacting phthalocyanines with complex alcoholates results in yields
ranging from 4% to 81% when using lithium methoxide in the presence of tetralin as
the solvent at 180 °C.193
Pc’s can also be prepared by heating 1,3-diiminoisoindoline in an organic
heteropolar solvent like isoamyl alcohol and dimethylformamide in the presence of
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reducing agents such as sodium sulfide.194 A mixture of 1,3-diiminoisoindoline nitrate
with an 80% solution of urea in water, stirred in the presence of sodium hydroxide,
results in phthalocyanines.195 Another method used in the preparation of pc’s requires,
reacting diiminoisoindoline with dimethylformamide and dichloroisoindole in benzene
and refluxing for 9 hours, filtering, and treating the residue with aqueous sodium
hyposulfite.196 Pc’s may be purified by boiling with sodium chloride and HC1 solutions,
followed by heating in a stream of inert gas, followed by sublimation resulting in the
improvement of electrophysical characteristics. Pc’s can also be purified by refluxing in
a strong base in alcoholic solution.197

UV/VIS Spectroscopy
Electromagnetic radiation is composed o f photons moving in a wave that
oscillates along the path of motion. The wavelength of light is defined through the
equation X = c/v where X is the wavelength, c is the speed o f light and v is the
frequency. Photons of different wavelengths have different energies that are given by:
E = he/ X = hv where h is the Max Planck constant. The shorter the wavelength, the
greater the energy of the photon.

Electromagnetic radiation can be divided into

various regions according to wavelength: the ultraviolet region has wavelengths of
200-400 nm, the visible region has wavelengths o f400-700 nm.198
Molecules have kinetic energy and energy associated with the bonding of
electrons. The absorption of light affects the energy of bonding electrons, but it does
not affect the kinetic energy.

Absorption of electromagnetic radiation involves a

change in one or more bonding energies.199 A molecule whose electronic, vibrational
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and rotational energies are all at their lowest values is said to be in the ground state.
When a molecule is irradiated, the photons may be absorbed and the molecule raised
to a higher energy level. Whether any electronic transition can occur in the visible or
ultra violet region depends on the nature of bonding electrons in the ground state.200
In general, the absorption of ultraviolet and visible light takes place with molecules
with chromophoric groups such as purines and pyrimidines. Any molecule containing
one or more of such groups will have an absorption band somewhere in the visible or
ultraviolet regions.201
For a single cuvette path length, the transmitted intensity decreases exponentially
with increasing concentration of an absorbing solute. The absorbance is defined as A=
log(Io/It) = eel where A is the absorbance or optical density, Io is the intensity o f
incident light, It is the transmitted intensity, and e is the molar absorptivity (or molar
extinction coefficient) with units M'1 cm 1, and the concentration c, is in molarity (M).
The Beer-Lambert law shows that absorbance is linearly related to concentration (or
path length).202
Since absorption strongly depends on wavelength for nearly all compounds, we
must specify the wavelength at which measurement is made. This is done using a
subscript X, indicating the particular wavelength, as A x or e x. For a single substance at
a specified wavelength, ex is a constant, characteristic of the absorbing sample, and is
independent of both c and 1. The wavelength dependence of ex or Ax is known as the
absorption spectrum of the compound. Deviation from the Beer-Lambert law can
occur for a variety of reasons such as inhomogeneous samples, light scattering by the
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sample, dimerization or other aggregation at high concentrations or changes in
equilibria involving dissociable absorbing solutes. 203
A wavelength at which two or more components have the same extinction
coefficient is known as an isosbestic wavelength, [ex M= ex N= e^].

At this

wavelength, the absorbance can be used to determine the total concentration of the two
components. Measurements at an isosbestic wavelength plus one other wavelength
where the extinction coefficients differ for the two components provide a particularly
simple solution to their Beer-Lambert law equations.
[M] _ s f A ^ - 6 ^ A,
[N]
Two common uses of isosbestics are the study of equilibria involving absorbing
compounds and investigations of reactions involving absorbing reactants and products.
The presence of isosbestics is used as evidence that there are no intermediate species
of significant concentration between the reactants and products.204

Binding Constants:

The three simplest complex stoichiometries are SL, SL2 and S2 L. If it is assumed that
every complex is formed in a bimolecular process, then the three complexes are related
by the following equilibria:
S+L
SL+L

S + SL

»"
*

SL
SI*

J-

w

s 2l
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We define the stepwise binding constants as:

K „ = [SL]/[S][L 1 K 12 = [SL2]/[SL ][L l

( 1)

K„ =[S2L]/[S][SL],
where these constants should be defined in terms of activities.
The formation of a higher complex can directly be written from the substrate and
ligand as

mS + nL

r

SmLn and the overall binding constant is defined as

where S is the substrate, L is the ligand interacting with the
substrate, m and n are the stoichiometries of S and L. The observed equilibrium binding
constant

or K^s for drug-DNA interactions can be extracted through construction of

Scatchard plots. The concentration of the bound species Cb is calculated in different
ways depending on the method used. The concentration of the free drug Cf is calculated
by using the relationship Q= Cb +Cf. The term r = Cb/[DNA] is plotted on the abscissa
and r/Q is plotted on the ordinate and the KobSis calculated from the intercept on the
ordinate as shown later in this section. Several methods have been used to calculate the
apparent binding constants.205
Absorbance in the visible region is a convenient tool for detecting complex
formation between a dye and DNA.

Most small molecules that bind to DNA by

intercalation have a visible absorption band by virtue of their heterocyclic structure. As
increasing amounts of DNA are added to free drug a shift in Xmx to longer wavelength
(red shift), and a decrease in absorbance (hypochromic effect) typically occurs. This
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presumably occurs due to the interaction of the drug with the electron system of the base
pairs. Drugs that do not bind to DNA show insignificant red shifts and hypochromic
effect. Sometimes all spectra of a drug-DNA titration pass through a common point, also
known as isosbestic point. The most common circumstance under which an isosbestic
point is obtained is when there are only two forms of the dye, in the case free in solution
and bound In other words if there is not an isosbestic point, even though the spectra of
complex and free dye cross, then there must be more than two forms of the dye. Blake
and coworkers discovered that the isosbestic point for the binding of proflavine to DNA
disappears at high loads of the drug. This might be due to outside stacking of the drug on
the surface of DNA, suggesting two modes of binding. From the UV-visible titration,
concentration o f the bound drug can be calculated from the expression Cb = AA/Ae where
AA is the change in the absorbance after the addition of the drug and Ae is the difference
in the molar extinction coefficient of the free and the bound drug. The Benesi-Hildebrand
model as shown in equation (2) is also used at low drug load (r) to calculate the binding
constants from UV-visible titration data.

[DNA]C,
AA

1
( [DNA]
A eK „
Ae

where Ct is the total drug concentration, [DNA] is the concentration of DNA, and AA is
the difference in the absorbance of the free and the bound drug at a given point. A plot of
[DNA]Ct /AA vs[DNA] has a linear variation with slope 1/Ae and intercept 1/K^pAe.
The ratio of the slope to intercept is the binding constant for the process. Equation (2)
suffers from the disadvantage that the extrapolation to infinite DNA concentration is not
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clear cut, since the equation is linear in [DNA], Hence a variation o f this approach
known as the half reciprocal approach shown in equation (3) is used to calculate Ae and
Kapp-

{DNA]
ASapp

[DNA]
AeKapp

1
Ae

where Aeappis the difference between the molar extinction coefficient of the free drug and
the apparent bound drug.206
Frequently, cooperativity is calculated using the Hill model.207 The Hill equation
is
l o g j ^ j = a Hlog(Cf)+ logK

(4)

where <Xh is the cooperative factor, f = r/n where r = Cb/[DNA], K is the apparent binding
constant and n is the binding site size. <xh values greater than 1 indicate cooperative
binding. However, care must be taken in using a Hill model for calculating K as this is a
log-log plot and hence the errors increase in an exponential manner. A direct plot can be
used to calculate binding constants for two distinct sites where r vs log Cf is plotted and
fitted to an uncoupled transition model as per the equation:
r=

n,K,Cf > ( n 2K 2Cf >
+
1 + K .C J
l + K 2Cf>

(5)

where ni Kt, and n2 , K2 are the binding site sizes and the binding constants of the two
different binding sites, Cf is the concentration of the free ligand 208
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Atomic Force Microscopy

Since atomic force microscopy (AFM) provides the ability to investigate surface
structure at nanometer to sub-angstrom resolution in ambient and liquid environments, it
has been used routinely over the past two decades in many scientific fields. Indeed, AFM
has contributed to ground-breaking research in the investigation of DNA, proteins, and
cells in biological studies, structure and component distribution in polymer science, pico
newton force interactions and surfactant behavior in colloid science, and physical/
mechanical properties and fabrication variables in the material sciences. Pharmaceutical
research often consists of a combination of these scientific branches, making it a
particularly viable field for the application of AFM. The ability o f AFM to provide highresolution, three-dimensional surface structure, regardless of sample conductivity, makes
it a powerful complement to other common analytical techniques currently available.209
AFM is the most commonly used form Of the scanning probe microscopy (SPM)
family of techniques. The origin o f SPM began with the development of the scanning
tunneling microscope (STM) by researchers at IBM.210 The ability o f the STM to
resolve atomic structure on a sample surface earned the inventors the Nobel Prize in
1986. However, the STM can only be applied to conductive or semiconductive
specimens. To broaden this type of microscopy to the study of insulators, the atomic
force microscope was developed in collaboration between IBM and Stanford University
in 1986.211 AFM is performed by scanning a sharp tip on the end of a flexible cantilever
across a sample surface, while maintaining a small, constant force The tips typically have
an end radius of 5 nm to 10 nm, although this can vary depending on tip type. The
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scanning motion is conducted by a piezoelectric tube scanner that scans the tip in a raster
pattern with respect to the sample as depicted in Figure 23. The tip-sample interaction is
monitored by reflecting a laser off the back o f the cantilever onto a split-photodiode
detector. The two most commonly used modes of operation are Contact Mode AFM and
Tapping Mode AFM, which are conducted in air and liquid environments. In contact
mode AFM, a constant cantilever deflection is maintained by a feedback loop that moves
the scanner vertically (z) at each lateral (x, y) data point to form the topographic image.
By maintaining a constant deflection during scanning, a constant vertical force is
maintained between the tip and sample. Applied forces during imaging typically range
between 0.1 and 100 nN. Although contact mode has proven useful for a wide range of
applications, it sometimes has difficulty on relatively soft samples.212
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Controller

Detector

Figure 23. Components of a Atomic Force Microscopy Instrument.
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Tapping Mode AFM consists of oscillating the cantilever at its resonance frequency
(typically -300 kHz) and scanning across the surface with a constant, damped amplitude.
The feedback loop maintains a constant root-mean-square (RMS) amplitude by moving
the scanner vertically during scanning, which correspondingly maintains a constant
applied force to form a topographic image. The advantage of Tapping Mode is that it
typically operates with a lower vertical force than that possible with contact mode, and it
eliminates the lateral, shear forces that can damage some samples.213 Thus, Tapping
Mode has become the preferred technique for imaging soft, fragile, adhesive, and
particulate surfaces. Although the initial use of SPM was to produce high-resolution
topographic images, a number of SPM techniques have been developed to study physical
and materials properties about sample surfaces. These techniques are commonly used to
investigate differences in friction, adhesion, elasticity, hardness, magnetic and
electrostatic fields, carrier concentration, conductivity, and temperature distribution.
Fundamental force studies are also conducted to study adhesive, attractive, and repulsive
interactions between specimens.214 One of the important innovations that has been
integrated into commercial atomic force microscopes is environmental control of the
sample. Imaging at elevated temperatures has made it possible to study thermal phase
transitions in ambient or inert gas conditions. Imaging in fluid at elevated temperatures
has provided the ability to image structures at a physiological temperature of 37°C.
Atmospheric hoods are also commonly used in AFM to control humidity or to conduct
experiments under specific atmospheric conditions.215
Interactions between biological specimens, such as ligand-receptor and proteinDNA systems, have frequently been studied by AFM, and can also be applied to the
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study of drug interactions with a variety of biological specimens. For example, AFMbased immunological studies have investigated antibody-antigen binding interactions,
and drug-DNA complexes have been studied with AFM to determine DNA ligand modeof binding 216 This is of considerable interest since nucleic acid ligands are commonly
used as anticancer drugs and in the treatment of genetic diseases. However, determining
whether they bind to DNA by intercalation within major and minor grooves, by
“nonClassical” modes, or by a combination o f these modes can often be difficult and
labor intensive. AFM was used to study drug binding mode, affinity, and exclusion
number by comparing the length of DNA fragments that have and have not been exposed
to the drug.217 It is known that if intercalative binding is occurring, the DNA strand
increases in length. Furthermore, the degree of lengthening is informative in determining
the binding affinity and the site-exclusion number. AFM was shown to be an effective
means of seeing and measuring any changes in the DNA strand. When exposed to
ethidium, a well characterized intercalator, the DNA strand was shown through AFM to
have increased in length from 3300 nm to 5250 nm as indicated by Figure 24.218
Similarly, AFM intercalative binding studies showed the increase in the DNA
strand, from 3300 nm to 4670 nm, upon exposure to daunomycin, an anticancer drug
used to treat leukemia. This technique has also successfully been applied to new drugs in
which the mode of binding was unclear. Exposure of 2,5-bis(4-amidinophenyl) (APF), a
new drug for the treatment of Pneumocystis carinii pneumonia, did not produce
lengthening of the DNA strands, indicating that the drug binds by nonintercalative
modes. Although, many AFM studies have concentrated on
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(A)

(B)

Figure 24. DNA strand before exposure to ethidium bromide (A) and after exposure to
ethidium bromide (B).

interactions at the molecular level, responses of living cells have also been visualized.219
Since cells can be imaged in a physiological solution at 37°C, it is possible to monitor the
interaction between a metabolically active cell and a chemical or biological additive to
the solution environment. Work has been published on observing the interaction between
living cells and drugs, viruses, and other chemicals. Rotsch and Radmacher conducted
“force mapping” studies on 3T3 and NRK fibroblast cells to visualize the effects of
various drugs.220 Force mapping, also referred to as “the force volume technique,”
conducts a lateral array of force curves across a sample surface that results in a forceinteraction image. Collecting force curves consists of recording the change in the
cantilever deflection as it moves vertically toward the sample until it touches the surface,
and then pulls away from the surface and retracts back to its starting position. Force
curves can detect repulsive, attractive, and adhesive interactions in the picoNewton-tonanoNewton range.221
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AFM is also commonly used to gain a better understanding of the physiological
mechanisms associated with disease. Some examples of this include AFM studies
associated with Alzheimer’s disease, Parkinson’s disease, diabetes, pancreatitis, and
cancer 222 One of the advantages in using an atomic force microscope for this type of
work is its ability to perform these investigations in situ. Yip and McLaurin used AFM
to study the mechanisms of amyloid-13 (A13) fibrillogenesis, which plays a role in
Alzheimer’s disease. In situ Tapping Mode imaging was performed on total brain lipid
bilayers to study the role of membrane composition and peptide structure. Brain lipid
bilayers were deposited onto mica and imaged in phosphate buffer solution (PBS). After
introducing the monomeric A13 peptides into the buffer solution, A61-40 molecules were
found to be partially inserted into the bilayer surface. After 15 hours, fibril growth was
initiated from these sites, resulting in membrane disruption . To study the specificity of
lipid bilayer composition and Afi sequence, the same experiment was conducted with
DMPC bilayers and A131-28 peptides. From these studies it was determined that the fibril
formation occurs in the presence of acidic lipids, and that the peptide requires the
hydrophobic C-terminal domain, which is critical for anchoring to the lipid to induce
fibrillogenesis. Without these critical requirements, membrane disruption is produced by
the formation of AJ3 aggregate without evidence of fibril formation. Based on these AFM
observations, a better understanding of the mechanisms that result in the AJ3
fibrillogenesis was formed.223
Atomic force microscopy (AFM) has many uses in the field of pharmaceutical
research, including the investigation of in situ processes, interaction mechanisms,
behavioral properties, and structure-function relationships. Although these examples are
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just a sampling of the work that has been conducted in drug interaction and disease
mechanism studies, they indicate how important the atomic force microscope has been to
medicine. The complementary nature of AFM with other analytical techniques will
certainly result in more discoveries and applications as it is used more by the scientific
community and as new AFM/SPM techniques are developed.224

Competitive Dialysis

The competition dialysis assay is a simple, inexpensive technique that allows for
the fast screening of drugs as potential anticancer agents. It was founded

on the

thermodynamic principle of equilibrium dialysis. A DNA-molecule solution is placed
inside a semipermeable dialysis membrane with pore sizes that allow small molecules to
pass through, but which retain the large DNA molecules as depicted in Figure 25.225
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Figure 25. Schematic diagram of the experimental arrangement for the competition
dialysis assay.
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The dialysis unit is then suspended in a solution containing a small molecule
ligand. The solution is mixed and allowed to equilibrate for a 24 hour period. After 24
hours when the solution has reached equilibrium, the chemical potential o f the free ligand
must be equal inside and outside each dialysis unit, and any excess ligand on the DNA
molecule side of the membranes may be attributed to binding with the DNA molecule.
Equilibrium dialysis has been used extensively to determine the binding of small
molecules or ions to macromolecules to provide valuable information for determining
relative binding affinities.226
In early 1982, Crothers and coworkers discovered a variant of the equilibrium
dialysis experiment, the competition dialysis process.227 The process developed was
used to determine the base specificity o f drug-DNA interactions. The assay used a threepart dialysis compartment, in which two dialysis membranes separated the central
compartment from two outside compartments228 Two DNA samples of

the same

concentration but of different base composition were placed in each of the two outer
compartments. A ligand solution was placed in the central compartment, and allowed to
equilibrate among the three compartments. If the ligand bound selectively to AT or GC
base pairs, more ligand would accumulate in the compartment containing the DNA with
the base composition containing the highest percentage of the preferred base.
Quantitative information about the essential mode of binding site are possible by this
method using simple probability theories. Competitive dialysis provides an avenue for
studying how ligands bind to nucleic acids and also provides a fast, inexpensive way of
screening potential drug targets.229

80

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

n . Methods and Materials

DNA oligomers were either synthesized and purified in the lab or were purchased
as their HPLC purified forms from Research Genetics Inc (Carlsbad, Ca). Oligomers
synthesized in the lab, after HPLC purification, were exhaustively dialyzed versus water
and then lyophilized to dryness. The purity of oligomers was checked by polyacrylamide
gel electrophoresis under denaturing conditions. The typical sample preparation involved
the reconstitution of the sample in all potassium buffer (lOmM KH2 PO4/K2 HPO4 , 0.1
mM EDTA) with specific concentration of KCI and/or M gCh added for respective
oligomers. Quantifications of solutions were done by UV spectrophotometry at 260 nm
and 95 °C using the extinction coefficient values for single-stranded oligomers as 7.36 x
104, 8.21 x 104, 1.43 x 105, 1.1 X105 and 2.35 x 105 M(strand)-1 for d(T4G4), d(T4G4T),
d(G4T4G4) and d(G2 T2 GzTGTG2T2 G2 ), respectively. The formation of quadruplex was
carried out by heating the samples at 95 °C for 5 minutes, allowing to cool to room
temperature, and then incubating for 48 hrs at 4 °C before use. The quadruplexes were
characterized by 16% PAGE gel electrophoresis under native conditions and by circular
dichroism.

Design o f DNA oligomer

Oligomers of sequence d(T4G4T) form parallel quadruplexes under the conditions
applied while d(G2 T2G2 TGTG2 T2 G2 ) gives rise to an antiparallel quadruplex structures
under the similar conditions.

Binding studies of porphyrazines to these different
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quadruplexes would help in understanding the modes of binding in these different
secondary structures, which could be totally different from one another. Both d(G4 T4 G4 )
and d(T4 G4 T) form parallel quadruplexes but the 3' end is blocked by thymines in the
later case. Studying the interaction of porphyrins in these systems can help in
understanding the binding mode in the case of d(T4G4 ), which has been a matter of
question in recent literature studies. Similar questions could be answered for
d(G2 T2G2 TGTG2 T2G2 ) which is an antiparallel quadruplex system. Linearized plasmid
PRs-316 was used to study the prorphyrazine-DNA interaction through AFM imaging
studies.

Materials and Methods for the synthesis of porphyrazines

Acetonitrile, l,8-diazabicyclo(5.4.0)undec-7-ene (DBU), iodoethane, nitromethane,
methanol, 1-octanol, 2-iodoethanol, iodomethane, 3,4-pyridine dicarbonitrile, copper
acetate, cobalt acetate, manganese acetate and zinc acetate were purchased from SigmaAldrich.(Milwaukee, WI). 2-Iodoethanol was distilled under reduced pressure and filtered
prior to use.
IR spectra were recorded from KBr pellets on a Nicolet-Magna IR 560 FT-IR.
UV-Visible spectra were determined with a Cary 100 Spectrometer. Elemental analyses
were conducted using a Perkin Elmer Series II elemental analyzer. ESI-MS

were

recorded on a Finnigan LCQ DECAXP spectrometer and MALDI-MS were recorded on
a Applied Biosystem Voyager DESTR.
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We have discovered a novel one-step, self-assembly synthesis of unmetallated
porphyrazines. In contrast to the previously published methods, our approach to the
synthesis of tetracationic metal-free and metal containing porphyrazines involves the
treatment of 3,4-dicyanopyridine with l,8-diazabicyclo(5.4.0)undec-7-ene (DBU) in
anhydrous

octanol at 185 °C for 2 hours. To obtain a tetracationic metal-free

porphyrazine, the resultant porphyrazine is treated with an excess of 2-iodoethanol in the
presence of nitromethane at 101 °C for a period of 24 hours. The tetracationic species
thus obtained is dissolved in methanol and water and reacted under reflux with the
corresponding metal acetate. We also prepared the same porphyrazines by reacting 3,4dicyanopyridine with the corresponding metal acetate, followed by reacting the metal
porphyrazine obtained with 2-iodoethanol in the presence of nitromethane at 101 °C for a
period of 24 hours, followed by cooling, filtration and removal of any impurities by
soxhlet extraction.
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Synthesis of Metallated and Non metallated Porphyrazines
Reaction Scheme I

HO

1) ICHjCHjCH

CHjNO,
N

OCTANOL

2)

M ACETATE

CHfHIHp

182-186°C

/

60-64°C
Of
Z M = H , 3: M= M i2*

4; M=Coff5 M= CU*

&M=Zh^

Experimental:

Tetrapyridino (3,4-b:3,,4’-g:3”,4”-l:3” %4,” -q)porphyrazine (1)
3,4-pyridinedicarbonitrile (500 mg, 3.8 mmol) was mixed in anhydrous octanol (25 mL),
followed by the addition of mmol DBU (2.36 g, 15.2 mmol). The mixture was slowly
heated over 40 minutes to reflux (185 °C) and held for an additional 2h. The mixture was
allowed to cool to room temperature and the precipitate was isolated by filtration.
The violet solid obtained was washed with octanol (30 mL) and purified by continuous
extraction in a Soxhlet apparatus with hexane (30 mL), then acetone (30 mL), and finally,
deionized water (30 mL). The resulting solid (1) was dried under vacuum to a constant
weight: (0.345 mmol, 225 mg), (yield 45%).
Decomposition temperature > 270 °C. Calculated for C2 8 H 1 4 N 1 2 : M = 518; Found:
MALDI-TOF-MS: rn/z 520 (M + 2H)+; ESI-MS: m/z 519 (M + H)+. UV-visible (10%
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acetic acid in deionized water) A,max (nm), (log

8

(dm3 mol' 1 cm'1)): 314 (0.680), 350

(0.680), 355 (0.674), 368 (0.667), 614 (0.752). JR. (KBr) v (cm'1): 2352, 1787, 1696,
1601, 1496, 1393, 1078, 737, 487. Elemental analysis: Calculated for C28 H 14N 12 -IH 2 O:
C, 62.68; H, 2.98; N, 31.34; Found: C, 62.35; H, 2.44; N, 31.09.

Tetraethanolpyridino (3,4-b:3%4’-g:3”,4”-I:3’” ,4,” -q)porphyraziniuin Iodide (2)
Porphyrazine 1 (150 mg, 0.289 mmol) was partly dissolved in 50 mL of nitromethane
followed by addition of excess 2-iodoethanol (7.70 mL, 0.098 mol).The mixture was
slowly heated over lh to reflux. The reaction was monitored by UV-visible spectroscopy.
It was observed that the tetracationic species formed causes a red shift of the Soret band
and reduces the number of Q bands. The reaction was complete after refluxing for 2h. It
was cooled to room temperature and the precipitate was isolated by filtration. The green
solid obtained was washed with nitromethane (30 mL) and purified by continuous
extraction in a Soxhlet apparatus with nitromethane (30 mL), then with hexane (30 mL).
The resulting solid (2) was dried under vacuum to a constant weight: (0.228 mmol, 275
mg), (yield 79%). Decomposition temperature > 250 °C. Calculated for C36 H3 4 N 12 O4 I4 :
M = 1205; Found: ESI-MS: m/z 697 (M - 4I)+. UV-visible (deionized water) A.max (nm),
(log s (dm3 mol'1 cm'1)): 347 (2.740), 368 (3.518), 684 (7.026). JR (KBr) v (cm'1): 3416,
1628, 1478, 1457, 1307, 1225, 1166, 1112, 1068, 1020, 904, 722, 676, 576. Elemental
Analysis: Calculated for C3 6 H34 N 12 O4 I4 O.5 H2 O: C, 35.58; H, 2.88; N, 13.83; Found: C,
35.41; H, 2.53; N, 14.06.
Manganese Tetraethanolpyridino (3,4-b:3’,4’-g:3”,4”-l:3,” ,4’” -q) porphyrazinium
Iodide (3)
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Porphyrazine 2 (100 mg, 0.0829 mmol) was dissolved in 35 mL of methanol and 5 mL
deionized water. Manganese acetate (22 mg, 0.0912 mmol) was added to the solution.
The

mixture

was

slowly

heated

over

lh

to

reflux.

The

reaction

was

monitored by UV-visible spectroscopy. The reaction was complete after refluxing for 6
hours. The reaction mixture was allowed to cool to room temperature, filtered (no
residue) and concentrated under reduced pressure. The resulting green solid obtained was
washed with 2-propanol (30 mL) and purified by continuous extraction in a Soxhlet
apparatus with 2-propanol (30 mL). The resulting solid (3) was then dried under vacuum
to a constant weight: (0.0651 mmol, 82 mg), (yield 78%). Decomposition temperature >
270 ° C. Calculated for C3 6 H3 2 N 12 O4 M11I4 : M = 1259. Found: ESI-MS: m/z 751(M 4I)+. UV-visible (dionized water) A,max (nm), (log e (dm3 mol'1 cm'1)): 225 (209.48),
368(45.02), 620 (84.90). JR (KBr) v (cm'1): 3384, 3000, 1624, 1473, 1422, 1304, 1168,
1135, 1066, 833, 773, 720, 668, 528, 424. Elemental analysis: Calculated
for C3 6 H3 2 N 12O4 M11I4 : C, 34.30, H, 2.54; N, 13.07; Found: C, 34.45; H, 2.55; N, 13.07.

Cobalt

Tetraethanolpyridino

(3,4-b:3’,4’-g:3”,4”-l:3” %4” ,-q) porphyrazinium

Iodide (4)
Porphyrazine 2 (100 mg, 0.0829 mmol) was dissolved in 35 mL of methanol and 5 mL of
deionized water. Cobalt acetate (22 mg, 0.0912 mmol) was added to the solution. The
mixture was slowly heated over lh to reflux. The reaction was monitored by UV-visible
spectroscopy. The reaction was complete after refluxing for 7 hours. The reaction mixture
was allowed to cool, filtered (no residue) and concentrated under reduced pressure. The
resulting green solid obtained was washed with 2-propanol (30 mL) and purified by
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continuous extraction in a Soxhlet apparatus with 2-propanol (30 mL). The resulting solid
(4) was then dried under vacuum to a constant weight: (0.0619 mmol, 782 mg) was
obtained, (yield 75%). Decomposition temperature > 285 °C. Calculated for
C3 6 H32 N 12 O4 C0 I4 : M = 1263; Found: ESI-MS: m/z 755(M - 4I)+. UV-visible (deionized
water) l maK (nm), (log s (dm3 m ol 1 cm'1)): 351 (5.271), 368 (5.895), 659 (8.610). IR
(KBr) v (cm'1): 3384, 3000, 1624, 1473, 1422, 1304, 1168, 1135, 1066, 833, 773, 720,
6 6 8

, 528, 424. Elemental aanlysis: Calculated for C3 6 H32 N 12 O4 C0 I4 : C, 34.19; H, 2.53;

N, 13.30; Found: C, 34.45; H, 2.53; N, 13.33.

Copper

Tetraethanolpyridino

(3,4-b:3’,4’-g:3”,4”-I:3” %4’” -q) porphyrazinium

Iodide (5)
Porphyrazine 2 (150 mg, 0.124 mmol) was dissolved in 35 mL o f methanol and 5 mL of
deionized water. Copper acetate (27 mg, 0.136 mmol) was added to the solution. The
mixture was slowly heated over 1 h to reflux. The reaction was monitored by UV-visible
spectroscopy. The reaction was complete after refluxing for 8 hours. The reaction mixture
was allowed to cool to room temperature, filtered (no residue), and concentrated under
reduced pressure. The resulting blue solid obtained was washed with 2-propanol (30 mL)
and purified by continous extraction in a Soxhlet apparatus with 2-propanol (30 mL).
The resulting solid was then dried under vacuum to a constant weight to give 109 mg
(0.0859 mmol) of (5), (yield 69%). Decomposition temperature > 295 0 C. Calculated for
C3 6 H3 2 N 12 O4 CUI4 : M = 1267. Found: MALDI-TOF-MS: m/z 759.20 (M- 4I)+, 716.82
(M- 41- CH2 CH2 OH)+, 671.68 (M - 41 - 2CH2 CH2 OH)+, 626.71 (M - 41 3CH2 CH2 OH)+, 581.76 (M- 41 - 4CH2 CH2 OH)+;

ESI-MS: m/z 760(M - 4I)+. UV-
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visible (deionized water) XmaK (nm), (log s (dm3 mol' 1 cm'1)): 259 (209.50), 368 (45.024),
620 (84.898). IR (KBr) v (cm'1): 3384, 3000, 1624, 1473, 1422, 1304, 1168, 1135, 1066,
833, 773, 720,

6 6 8

, 528, 424.

Elemental analysis: Calculated for C3 6 H32 N 12 O4 CUI4 : C,

34.07; H, 2.52; N, 13.25; Found: C, 34.82; H, 2.44; N, 13.10.

Zinc Tetraethanolpyridino (3,4-b:3,,4,-g:3”,4”-l:3” %4’” -q) porphyrazinium Iodide
(6)
Porphyrazine 2 (100 mg, 0.0829 mmol) was partly dissolved in 35 mL of methanol, and 5
mL deionized water. Zinc acetate (182 mg, 0.0911 mmol) was added to the solution. The
mixture was slowly heated over 1 h to reflux. The reaction was monitored by UV-visible
spectroscopy. The reaction was complete after refluxing for 8 hours. The reaction mixture
was allowed to cool to room temperature, filtered (no residue) and concentrated under
reduced pressure. The dark green solid obtained was washed with 2-propanol (30 mL)
and purified by continuous extraction in a Soxhlet apparatus with nitromethane (30 mL).
The resulting solid obtained was then dried under vacuum to a constant weight to give
760 mg (0.0598 mmol) of 6 , (yield 72%). Decomposition temperature > 296 °C.
Calculated for C3 6 H3 2 N 12 O4 Z11I4 : M = 1270; Found: MALDI-TOF-MS: m/z 760.30 (M4I)+, 716 (M- 41- CH2 CH2 OH)+, 671.02 (M - 41 - 2CH2 CH2 OH)+, 626 (M - 41 3CH2 CH2 OH)+; ESI-MS: m/z 762 (M - 4I)+. UV-visible (deionized water) \ max (nm),
(log s (dm3 mol' 1 cm'1)): 379 (31.38), 608 (19.99), 657 (67.50), 670 (73.73). IR (KBR) v
(cm'1): 3731, 3419, 3000, 2272, 1631, 1478, 1300, 1166, 1109, 1072, 713, 672, 653.
Elemental analysis: Calculated for C3 6 H32 N 12 O4Z 11I4 : C, 34.05; H, 2.54; N, 13.23; Found:
C, 34.38; H, 2.53; N, 13.19.
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Reaction scheme 11:

HO

1)

/ N -Macetate

o

> -M -N

F=M

ch , no 2

10 0 - 102 °C

1 2 5 -1 3 0 °C

7: M= Mn2+; 9: M = Co2+
11: M= Cu2+ 13: M=Zn2+

41-

r\^

r ^ z t^ r O '

8: M = Mn2+; 10: M = Co2+
12: M = Cu2+ 14: M = Zn2+

Manganese (II) 4,4% 4”,4’”-tetraaza-29H, 31H-phthalocyanine (7).

3,4-pyridinedicarbonitrile

(500 mg, 3.7 mmol) was dissolved in 60 mL of 2-

(dimethylamino)ethanol. Manganese acetate (226 mg, 0.925 mmol) was added to the
solution. The mixture was slowly heated over lh to reflux. The reaction was
monitored by UV-visible spectroscopy. The reaction was complete after refluxing for 72
hours. The reaction mixture was allowed to cool to room temperature, filtered and the
resulting green solid obtained was washed with 2-(dimethylamino)ethanol (25 mL) and
purified by continuous extraction for 24 hours in a Soxhlet apparatus with hexane (30
mL), followed by continous extraction with acetone (30 ml). The resulting solid was then
dried under vacuum to a constant weight to afford 521 mg (0.912 mmol) of 7 at (yield
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98%). Decomposition temperature > 270 ° C. IR (KBR) v (cm'1): 3421, 3070, 2944,
2576, 2227, 1168, 1342, 1165, 1021, 953, 786, 672, 654. Elemental analysis: Calculated
for C28Hi2Ni2 Mn: 3.5 H20 : C, 53.35, H, 2.97; N, 25.90; Found: C, 53.08; H, 3.00; N,
26.54.

Manganese Tetraethanolpyridino (3,4-b:3%4’-g:3”,4”-l:3’” ,4’” -q) porphyrazinium
Iodide (8).
Manganese (II) 4, 4’, 4”,4’”-tetraaza-29H, 3 lH-phthalocyanine 7 (300 mg, 0.275 mmol)
was partly dissolved in 40 mL of nitromethane followed by addition of excess 2iodoethanol (7.13 mL, 65 mmol). The mixture was slowly heated over lh to reflux. The
reaction was monitored by UV-visible spectroscopy. It was observed that the tetracationic
quartemized species formed because of a red shift of the Soret band. The reaction was
complete after refluxing for 24h. The reaction mixture was allowed to cool to room
temperature and the precipitate was isolated by filtration. The green solid obtained was
washed with nitromethane (30 mL) and purified by continuous extraction in a Soxhlet
apparatus with nitromethane (30 mL), then hexane (30 mL). The resulting solid was dried
under vacuum to a constant weight to afford 175 mg (0.228 mmol) of 8, (yield 51%).
Calculated for C3 r,H3 2 Ni2 0 4 MnI4: M = 1259. Found: ESI-MS: m/z 751(M - 4I)+. UVvisible (dionized water) Xmax (nm), (log s (dm3 mol'1 cm'1)): 225 (209.48), 368(45.02),
620 (84.90). IR (KBr) v (cm'1): 3384, 3000, 1624, 1473, 1422, 1304, 1168, 1135, 1066,
833, 773, 720, 668, 528, 424. Elemental analysis: Calculated for C36H32Ni204Mnl4: C,
34.30, H, 2.54; N, 13.07; Found: C, 34.40; H, 2.45; N, 13.01.
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Cobalt (II) 4,4% 4”,4’”-tetraaza-29H, 31H-phthalocyanine (9).
3,4-pyridinedicarbonitrile
(dimethylamino)ethanol.

(500 mg, 3.7 mmol) was dissolved in 60 mL of 2Cobalt acetate (231 mg, 0.929 mmol) was added to the

solution. The mixture was slowly heated over lh to reflux. The reaction was monitored
by UV-visible spectroscopy. The reaction was complete after refluxing for 72 hours. The
reaction mixture was allowed to cool, and filtered. The resulting green solid obtained was
washed with 2-(dimethylamino)ethanol (25 mL) and purified by continuous extraction in
a Soxhlet apparatus for 24 hours with hexane (25 mL), followed by continous extraction
with acetone (25 ml). The resulting solid was then dried under vacuum to a constant
weight to afford 485 mg (0.0619 mmol) of 9, (yield 91%). Decomposition temperature >
285 °C. IR (KBR) v (cm'1): 3442, 3090, 2933, 2588, 2227,1951, 1607, 1057, 1021, 976,
786, 672, 651. Elemental analysis: Calculated for C28 H 12N 12 C0

. H2 O: C, 53.38; H,

3 5

3.20; N, 25.59; Found: C, 53.71; H, 3.58; N, 25.09.

Cobalt

Tetraethanolpyridino

(3,4-b:3\4’-g:3”,4”-l:3’” ,4” ’-q) porphyrazinium

Iodide (10)
Cobalt (II) 4, 4’, 4”,4”’-tetraaza-29H, 31H-phthalocyanine 9 (200 mg, 0.347 mmol) was
partly dissolved in 50 mL of nitromethane followed by addition of excess iodoethanol
(8.15 mL, 116 mmol). The mixture was slowly heated in lh to reflux. The reaction was
monitored by UV-visible spectroscopy. It was observed that the tetracationic quartemized
species formed causing a red shift of the Soret band. The reaction was complete after
refluxing for 24h. The reaction mixture was allowed to cool to room temperature and the
precipitate was isolated by filtration. The green solid obtained was washed with
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nitromethane (30 mL) and purified by continuous extraction in a Soxhlet apparatus with
nitromethane (30 mL), hexane (30 mL). The resulting solid was dried under vacuum to a
constant weight: 0.254 mmol 10 (322 mg) was obtained (yield 73.50%).
Calculated for C3 6 H32 N 12 O4 C0 I4 : M = 1263; Found: ESI-MS: m/z 755(M - 4I)+. UVvisible (deionized water) A™ax (nm), (log s (dm3 mol'1 cm'1)): 351 (5.271), 368 (5.895),
659 (8.610). IR (KBr) v (cm'1): 3384, 3000, 1624, 1473, 1422, 1304, 1168, 1135, 1066,
833, 773, 720, 668, 528, 424.

Elemental analysis: Calculated for C3 6 H32 N 12 O4 C0 I4 : C,

34.19; H, 2.53; N, 13.30; Found: C, 34.20; H, 2.48; N, 13.11.

Copper

Tetraethanolpyridino (3,4-b:3’,4’-g:3”,4”-l:3,” ,4” ,-q) porphyrazinium

Iodide (12).
Copper (II) 4, 4’, 4”,4’” -tetraaza-29H, 3 lH-phthalocyanine 11 (100 mg, 0.170 mmol)
was partly dissolved in 30 mL of nitromethane followed by addition of excess 2iodoethanol (6.36 mL, 58.0 mmol). The mixture was slowly heated in lh to reflux. The
reaction was monitored by UV-visible spectroscopy. It is observed that the tetracationic
quartemized species formed causes a red shift of the Soret band. The reaction was
complete after refluxing for 48h. The reaction mixture was allowed to cool to room
temperature and the precipitate was isolated by filtration. The green solid obtained was
washed with nitromethane (30 mL) and purified by continuous extraction in a Soxhlet
apparatus with nitromethane (30 mL), followed by hexane (30 mL). The resulting solid
was dried under vacuum to a constant weight to afford 215 mg (0.169 mmol) of 12, (yield
69.59%). Decomposition temperature > 295

0

C. Calculated for C3 6 H32 N 12 O4 CUI4 : M =

1267. Found: MALDI-TOF-MS: m/z 759.20 (M- - 4I)+, 716.82 (M- 41- CH2CH2OH)+,
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671.68 (M - 41 - 2CH2CH2OH)+, 626.71 (M - 41 - 3CH2CH2OH)+, 581.76 (M- 41 4CH2CH2OH)+; ESI-MS: m/z 760(M - 4I)+. UV-visible (deionized water) A,max (nm),
(log s (dm3 mol'1 cm'1)): 259 (209.50), 368 (45.024), 620 (84.898). IR (KBr) v (cm'1):
3384, 3000, 1624, 1473, 1422, 1304, 1168, 1135, 1066, 833, 773, 720, 668, 528, 424.
Elemental analysis: Calculated for C36H32Ni204Cul4: C, 34.07; H, 2.52; N, 13.25; Found:
C, 34.60; H, 2.70; N, 13.21.

Zinc (II) 4, 4%4”,4”’-tetraaza-29H, 31H-phthalocyanine (13).
3,4-pyridinedicarbonitrile (1.0 gram, 7.4 mmol) was dissolved in 60 mL of 2(dimethylamino)ethanol. Zinc acetate (331 mg, 1.85 mmol) was added to the solution.
The mixture was slowly heated over lh to reflux. The reaction was monitored by UVvisible spectroscopy. The reaction was complete after refluxing for 72 hours. The
reaction mixture was allowed to cool, and filtered. The resulting green solid obtained was
washed with 2-(dimethylamino)ethanol (50 mL) and purified by continuous extraction in
a Soxhlet apparatus for 24 hours with hexane (50 mL), followed by continous extraction
with acetone (50 ml). The resulting solid was then dried under vacuum to a constant
weight to afford 312 mg (0.0619 mmol) of

13, (yield 80.0%). Decomposition

temperature > 290 °C. IR (KBR) v (cm'1): 3421, 3070, 2944, 2576, 2227,1168, 1342,
1165, 1116, 1057, 903, 836, 653. Elemental analysis: Calculated for C2gHi2Ni2Zn: C,
57.60; H, 2.06; N, 28.90; Found: C, 57.32; H, 1.96; N, 28.71.
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Zinc Tetraethanolpyridino (3,4-b:3’,4’-g:3”,4”-l:3” %4” ’-q) porphyrazinium Iodide
(14).
Zinc (II) 4, 4’, 4”,4’”-tetraaza-29H, 3 lH-phthalocyanine 10 (100 mg, 0.170 mmol) was
partly dissolved in 60 mL of nitromethane followed by addition of excess 2-iodoethanol
(9.54 mL, 87.2 mmol). The mixture was slowly heated over lh to reflux. The reaction
was monitored by UV-visible spectroscopy. It was observed that the tetracationic
quatemized species formed causes a red shift of the Soret band. The reaction was
complete after refluxing for 48h. The reaction mixture was allowed to cool to room
temperature and the precipitate was isolated by filtration. The green solid obtained was
washed with nitromethane (30 mL) and purified by continuous extraction in a Soxhlet
apparatus with nitromethane (30 mL), followed by hexane (30 mL). The resulting solid
was dried under vacuum to a constant weight to afford 100 mg (0.169 mmol) of 14,
(yield 50.0%). Decomposition temperature > 295 ° C. Calculated for C3 6 H32 N 12 O4 Z 11I4 :
M = 1270; Found: MALDI-TOF-MS: m/z 760.30 (M- 4I)+, 716 (M- 41- CH2CH2OH)+,
671.02 (M - 41 - 2CH2CH2OH)+, 626 (M - 41 - 3CH2CH2OH)+; ESI-MS: m/z 762 (M 4I)+. UV-visible (deionized water) Xmax (nm), (log 8 (dm3 mol'1 cm'1)): 379 (31.38), 608
(19.99), 657 (67.50), 670 (73.73). IR (KBR) v (cm'1): 3731, 3419, 3000, 2272, 1631,
1478, 1300, 1166, 1109, 1072, 713, 672, 653.

Elemental analysis: Calculated for

C3 6 H3 2 N 1 2 O4 Z11I4 : C, 34.05; H, 2.54; N, 13.23; Found: C, 34.45; H, 2.50; N, 13.46.
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UV-VIS Spectroscopy:
Absorption spectra were recorded at 25.0 ±0.1 °C using a Cary 100 UV/VIS
spectrophotometer fitted with a constant temperature accessory and interfaced with a
computer for data collection. Titration experiments for binding were performed in KBPES buffers with 200 mM K+ and/or 20 mM Mg++for d(T4 G4 ), and 100 mM K+ for the
aptamer. Optical monitoring was done at the respective Xmax for the Soret band of each
porphyrazine. Solutions of fixed concentration of porphyrazines (3-5 pM) were titrated
by stepwise addition of aliquots of DNA solution containing the porphyrazine at the same
concentration (30-50 pM in quadruplex or duplex). After each addition, the solution was
incubated for 5 minutes before any readings were taken. All of the titrations were done at
25 °C. Titration data was plotted and transferred to the program Power Point. Titration
data were then cast into the form of Scatchard plots of r/Cf versis r for analysis. Data
were fit through simple Scatchard equation:

r/Cf = K(n-r)

(6)

where K is the equilibrium binding constant and n represents the number of ligand
molecules bound per DNA quadruplex. The binding ratio r is defined as Cb/[DNA],
where the molar concentration of bound porphyrin, Cb, is equal to AA /Ae (AA is the
difference is absorption of the free porphyrin and porphyrin in the presence of DNA at
respective

of each porphyrin and Ae is the difference in molar extinction coefficients

between the free and bound porphyrin, ef - eb). The concentration of free porphyrin, Cf
was calculated using Ct = Cb + Cf where Ct is the total concentration of porphyrin. The
DNA concentration is expressed in terms of the molar concentration per quadruplex.
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These terms can also be determined by calculating first the fraction of bound drug a as
given directly by the relative AA hypochromicity term using AA = (Afree-A)/(Afree-Asat),
where Afree and Asat are the absorbances for free and fully bound ligands at respective
Xmax of each porphyrin. The term Cf is calculated by Cf = (1 -a). Ct and binding ratio r is
defined as (C - Cf)/[DNA]. No difference was found in the observed Scatchard plots
obtained by the two methods. Nonlinear least squares regression fit line was plotted for
all the fits and error bars (5% of the observed Y value) were added to maintain a 95%
confidence interval.
Atomic Force Microscopy (AFM) Experiments

DNA samples for imaging were prepared by diluting 2.5 pg aliquots of linearized
plasmid PRs-316 in water. The samples were denatured by boiling, followed by rapid
cooling and lyophilization. The lyophilized samples were then dissolved in the
appropriate buffer and incubated at 37 °C for 24 h. After incubation, the samples were
diluted 1:100 in lOmM Tris-HCl, pH 7.0, ImM MgCh, and 10 pi was deposited onto a
freshly cleaved mica surface. The DNA sample was allowed to absorb for 5 min, washed
with 1 mL sterile water and rapidly dried in a stream of N 2 gas. The same protocol was
adapted to image DNA in the presence of MTEPPI such that the [MTEPPI]/[DNA] = 2:1.
Porphyrazine solutions were made in the same buffer as DNA. Imaging was carried out
using a commercial ambient scanning probe microscope (Park Scientific Inst., Sunnyvale,
CA), employing Au-coated SisN4 cantilevers with sharpened pyramidal tips. The images
were recorded in the height and force imaging modes.

Additional image analysis

performed on an Intel 500 MHz Pentium Ill-based computer using the UTHSCSA Image
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Tool program (developed at the University of Texas Health Science Center at San
Antonio, Texas and available from the Internet by anonymous FTP from maxrad6.
uthscsa. edu).

Competition Dialysis experiments

For each competition dialysis assay, 400 mL of the dialysate solution containing 1
uM ligand (Drug) was placed into a 1 liter beaker. A volume of 180 uL of each of the
nucleic acid samples was pipetted into a separate 0.5 mL Spectro/Por DispoDialyze unit
with a 2000 molecular weight cut off. All the oligonucleotides (Table 1) were at the same
concentration of 75 uM. The nucleic acid concentration was expressed in terms of the
monomeric unit for each polymer. All 10 dialysis units were placed in the beaker
containing the dialysate solution. The beaker was covered with a glass covering and
wrapped in aluminum foil, kept away from light, and allowed to equilibrate with stirring
for 24 hours at room temperature (25 °C) in a temperature controlled bath. After
completing the equilibration time, the oligonucleotide samples were removed to
microfuge tubes and were diluted to a final concentration of 1% (w/v) with sodium
dodecyl sulfate (SDS) by the addition of the appropriate volumes of a 10% (w/v) stock
solution. For each separate ligand studied, the total concentration of TEPPI ( 7026 M1
cm1, 684 nm); MnTEPPI (84,900 M1 cm1 , 620 nm; CoTEPPI (8917 M1 cm1 , 659nm;
CuTEPPI ( 84,898 M1 cm1 , 621 nm; ZnTEPPI (73,730 M1 cm1 , 670 nm); within each
dialysis unit was then determined spectrophotometrically (Varian, Cary 100) using each
extinction coefficient at the specified wavelength. An appropriate correction for the slight
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dilution of the sample resulting from the addition of the stock SDS solution was made.
The free ligand concentration (Cf) was determined spectrophotometrically using an
aliquot of the dialysate solution. The concentration did not change from the initial 1 pM
concentration. The amount of bound drug (Cb )was determined by the difference o f :
Cb = C t - C f .

The data was plotted as a bar graph using Harvard Graphics. The apparent binding
constants were calculated using the following equation:
Kapp =

C b /C f X ( N A ) total.

Where Cb and Cf (1 pM) are the bound and free ligand concentrations, respectively, and
(NA) total (75 pM) is the nucleic acid concentration.
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Conformation
Single stranded

Duplex DNA

TetraplexDNA

DNA/oligo

X (nm)

8 *

Tm(°C)

Poly (da)

257

8,600

Poly (dt)

264

8,520

Poly (dg-dc)

254

16,800

>100

Poly (da-dt)

262

13,200

67.8

CalfThymus

260

12,824

85.5

T4G4

255

7,360

T4G4T

258

8,210

G4T4G4

254

11,520

(G2T2G2)2TGT

257

14,330

Table 1. DNA oligonucleotide physical properties used for competitive dialysis
i
1 1
study. * e = (dm mol' cm' )
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CHAPTER IV
RESULTS AND DISCUSSION

Porphyrazines synthesis:

A porphyrazine and a series of tetracationic porphyrazines, unmetallated and
metallated were synthesized as described in detail in Chapter

in

under Materials and

depicted below in Scheme I.
Reaction Scheme I:

1) ICHpHpH

OCTANOL

182-186°C

i

2:M = H ,

3: M= Mn2*

4: M=Co2t5 M= Cu2*
6:M=Zh»

The first part of our design was to build porphyrazine (1) with nitrogen in its peripherals for
reaction with iodoethanol while qualemizing the ring system at the same time. This was
accomplished by reacting 3,4-dicyattopyridine with l,8-diazabicyclo-(5.4.0)-undec-7-ene
(DBU) in anhydrous octanol at 185 °C for 2 hours, followed by purification to obtain the
neutral tetrapyridino porphyrazine (1) which was obtained in a yield of 45%. The
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tetracationic nonmetallated tetraethanoltetrapyridino porphyrazinium iodide (2) was
synthesized by reacting the neutral porphyrazine (1) with a large excess of 2-iodoethanol in
the presence of nitromethane.

After purification a yield of 79% was obtained. The

nonmetallated tetraethanoltetrapyridino porphyrazinium iodide (2) was then metallated with
the specific metal acetate in a solution of water/methanol solution at reflux. After
purification, the metallated porphyrazines obtained were Mn+2(3), Cu2+ (4), Co2+ (5), Zn2+(6)
with yields of 78%, 69%, 75% and 72%, respectively. In our second approach to obtaining
metallated porphyrazines, we followed the following reaction Scheme II, shown below.
Reaction Scheme II:

Macetate

ch3no2

1 0 0 -1 0 2 °C

1 2 5 -1 3 0 °C

8: M = Mn2+; 10: M = Co2+
12: M = Cu2+ 14:M=Zn2+

7: M = Mn2+; 9: M = Co2+
11: M = Cu2+ 13: M = Zn2+

This part of the synthesis was based on the synthesis of phthalocyanines, by
substituting phthalonitrile with 3,4 dicyanopyridine and reaction in the presence of
dimethylethanol amine and the corresponding metal acetate at reflux, followed by
purification to directly obtain the metallated porphyrazines. (Mn+2 (7), Cu2+ (11), Co2+ (9),
Zn2+ (13). The metallated porphyrazines w ere quartemized with a large excess o f iodoethanol

in the presence of nitromethane at reflux. Purification led to die metallated porphyrazines
(Mn+2 (7), Cu2+ (11), Co2+ (9), Zn2+ (13), with yields of 51%, 69%, 75% and 50%,
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respectively. The objective for synthesizing these porphyrazines was to demonstrate their
utility as potential DNA binding agents.

UV/Visible spectra of prophyrazines:

A great interest has been shown for compounds that have absorb light at long
wavelengths.

Recently

2,3-naphthalocyanines,

especially

the

tetrabenzo-annelated

phthalocyanines, have been proposed as photodynamic theurapeutic agents. The water
solubility of phthalocyanines depends on the type of substituents of the ligand on the
phthalocyanine core. In our laboratory, the porphyrazines were made water soluble by
quartemizing with specific ligands. The advantage of these molecules is that they are very
water soluble, making them attractive for carrying them through the cell membrane. The
porphyrazines that were synthesized in our laboratory show great promise as photosensitizers
because these compounds have intense absorptions between 600 -700 nm with extinction
coefficients greater than 10s L mol'1cm'1 (See Figures 28, 30, 32, 34, 36). Tetrapyridyl
porphyrazines exhibits the lowest extinction coefficient when quatemized with acetic acid,
(see Figure 38). By Incorporating ligands into this system leading to enhanced water
solubility, we were also able to increase the molar absorptivity and obtain higher molar
extinction

coefficients.

Figure

27

depicts

the

visible

absorption

spectra

of

tetraethanoltetrapyridino porphyrazine iodide (TEPPI) indicating absorbances at very low
molar concentrations of 4.66 X 10"6 M. Another physical property that makes these
porphyrazines attractive as photo dynamic theurapeutic agents is the fact that they have large
molar extinction coefficients even at low molar concentration. (See Figure 28).
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Upon complexation of the ring with manganese, a divalent metal, the ring system
becomes contracted by the bonds and in effect changes the molar absortivity of the ring
system as depicted in Figue 29 . Further, comparing a nonmetallated system (TEPPI) with
(MnTEPPI) one can note that the absorbance shifts by 40-50 nm to a lower wavelength when
incorporating manganese into tine ring system. When the metal is incorporated into the ring
system the molar extinction value goes up significantly as indicated by Table 2. The spectral
changes could be due to the partial charge transfer from the nitrogen atom to the
porphyrazine a-electron system. Additionally, the spectral changes may also be due to the
fact that porphyrazines exist in solution as nonequivalent tautomers arising from the
delocalization of the electrons.
The chemical changes that take place when incorporating a metal center, allows one
to control the optical absorption, ionization and the redox potentials of the molecule. The
quatemization of the porphyrazines also allows for many changes in aqueous systems. The
interaction between water and a charged species also affects the electronic nature of the
molecule as reflected in Figures 27,29,31,33 and 35.
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----- 4.66
----- 9.32
1.86
----- 3.73
----- 7.46
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X 10-6 M
X 10-6 M
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Figure 27. UV/Visible absorbance spectra of TEPPI in water.

y = 70tt.4x+0.044
R2=0.9988

y*6753.1x+0.0417
R2s 0.999
y»3507.5x+0.0038
R2S 0.999

y = 3320J x +0.0076
r 2=059©

0.6

-

0.4 0.2

♦ 683 nm

-

0.00E+00

■ 669 nm
5.00E-05

1.00E-04

1.50E-04

2.0

m o le s /lite r

383 nm
x 368 nm

Figure 28. Absorbance versus moles/liter of TEPPI.
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8.8 X 10-7 M
1.76x1 0-7
3 .5 2 x 1 0 -6

rV r-o r.^O
H

7.05 x 10-6
1.41 x 10-5 M

0-9
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-0.1260
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660

860

Wavelength (nm)

Figure 29. UV/VIS absorbance spectra of MnTEPPI in water.

y = 3702.9x

0.9 -|

R 2 = 0.9892

0.8

-

y = 2587.3X

0.7 -

0.6

R 2 = 0.9887
-

0.5 0.4 0.3 -

♦ 620 nm

0.2

■ 368 nm

-

Linear (620
0.00E+0 5.00E-05 1.00E-04 1.50E-04 2.00E-04 2.50E-04
Moles/Liter

Figure 30. Absorbance versus moles/liter of MnTEPPI.
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As noted above, the insertion of the divalent metal Mn decreases the wavelength of
maximum absorbance (A ^) and increases the extinction coefficient of the porphyrazine.
Examination of the data in Figures 31-38 and in Table 1, shows how the nature of the metal
influences the magnitude of the spectral changes. Changing from manganese to cobalt shifts
Xmax to a higher wavelength as depicted in Figure 31 and increases the extinction coefficient
As can be seen from Figure 33 and Figure 35, there is a shift by 10 nm in the wavelength
when substituting copper for zinc.
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Figure 31. UV/VIS absorbance spectra of CoTEPPI in water.

y=7592.9x+0.0292
R2 = 0.9944
y = 5271,2x + 0.027
R2 = 0.9949
y = 5271,2x + 0.027
R2= 0.9949

0
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-

0.2

-

♦
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■

O.OOE+OO 5.00E-05 1 .OOE-04 1.50E-04 2.00E-04

368 nm
351 nm
^ — Linear (659 nm)
— Linear (368 nm)
^ - L i n e a r (368 nm)

Moles/Liter

Figure 32. Absorbance versus moles/liter of CoTEPPI.
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8

oin
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Figure 33. UV/VIS absorbance spectra of CuTEPPI in water.
y = 60137x + 0.0144
R2 = 0.9996
y=61321x + 0.0164
R 2 = 0.9997
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0.7

y = 185 56 x -0.0003
R2= 0.9995

0.6

y=24959x + 0.0021
R2 = 0.9993

0.5
0.4

y = 24392x + 0.0042
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Figure 34. Absorbance versus moles/liter of CuTEPPI.
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Wavelength (nm)

Figure 35. UV/VIS absorbance spectra of ZnTEPPI in water.
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Figure 36. Absorbance versus moles/liter of ZnTEPPI.
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Figure 37. UY/VIS absorbance spectra of TPP in water.
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Figure 38. Absorbance versus moles/liter of TPP .
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COMPOUND

Q BANDS

SORET BAND

TPP*

614(0.75)

314(0.680); 350(0.676); 355(0.674); 368(0.667)

TEPPI

684(7.02)

347(2.74); 368(3.51)

MnTEPPI

620(3.70)

368(2.58)

CoTEPPI

659(8.91)

354(6.65)

CuTEPPI

667(28.90)

368(11.50)

ZnTEPPI

683(26.42)

393(26.42)

Table 2. Electronic spectral data of the porphyrazines in deionized water.
(£ = dm3 mor1cm'1).
*= In 10% acetic acid.

Our findings indicate that symmetrically substituted metallated or unmetallated
porphyrazines are readily available by the synthetic methods developed in our laboratory.
These compounds are characterized by long wavelength absorption with high molar
extinction coefficients values as indicated by Table 2. The solubility of these quartemized
porphyrazines in water also makes them better candidates for being able to move through the
cell membrane in carrier systems like PEG. The viability as having excellent singlet oxygen
quantum yields and good photooxidative stability is also another property that makes these
compounds potential photodynamic theurapeutic agents. Further, these compounds are
unique, because even at low concentrations, they still exhibit large absorption. This physical
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property allows one to use the compounds in very low concentration levels when targeting
tumor cells and also minimize cytotoxic effects.

Titration of DNA oligonucleotides with porphyrazines:

Titrations of DNA oligonucleotide with the above metallated and unmetallated
porphyrazines was monitored by visible absorption spectroscopy. The main focus of these
studies was to observe any changes of the Soret band of the porphyrazine in the presence of
excess DNA. The spectra are characterized by orange or red shifts and hypochromidties or
hyperchromicities of the Soret band. The changes in the Soret band of the porphyrazine
indicate the type of interaction within a ligand-DNA complex. The degree of hypochromicity
or hyperchromicity and extent of shift in Xmav indicates the types of interactions that take
place such as intercalation, outside binding or outside stacking. As indicated by Figure 69 one
can see the percent degree of hypochromicity or hyperchromicity due to the ligand-DNA
interaction.

This is followed by the uv/visible spectra of each TEPPI, ZnTEPPI and

CoTEPPI interactions with different DNA oligonucleotides.
As can be shown from Figures 39-

68

, porphyrazines bind to DNA duplexes and

DNA quadruplexes. Figure 69 clearly shows the degree that porphyrazines bind. The degree
and the way in which they bind can be determined by the degree of hypochromicity or
hyperchromicity.

The titration curves obtained as a result of the interaction of TEPPI,

ZnTEPPI and CoTEPPI with calf thymus are depicted in Figures 39, 50, and 59 respectively.
All of the curves show significant hypochromicity (decrease in absorbance) as well as a slight
red shift in the Xmax of respective porphyrazines, although the magnitudes vary in different
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cases. In addition, an isosbestic point is observed in most of the curves which is indicative of
a two state system (free and fully bound).
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Interaction of TEPPI with calf thymus:

6.00E-01 5.00E-01 4.00E-01
3.00E-01 -

5 2.00E-01
1.00E-01 -

300
-1.00E-01 J

400

500

600

700

800

900

Wavelength (run)

F ig u re 39.

UV/VIS spectra for the titration of TEPPI in the presence of
calf thymus.

DNA + DRUG
DRUG

Wavelength (run)

F ig u re 40.

UV/VIS spectra of calf thymus + TEPPI fully bound and TEPPI
unbound.

114

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 39 shows that as a solution of porphyrazine and calf thymus DNA reach
saturation when added into a porphyrazine solution at a constant porphyrazine concentration,
the absorption bands becomes indistinguishable from each other and that the absorption
begins to go up instead of continuallly going down. This phenomenon is probably due to
other electrostatic binding forces taking place. As depicted in Figure 40 the absorption of the
fully bound calf thymus DNA with TEPPI shows a higher absorption band than the free
TEPPI. This phenomena could be due to the following: as the calf thymus DNA becomes
saturated with TEPPI, the interactions that then take place are due to outside stacking and
electrostatic interactions in the minor groove.
As depicted in Figure 41, one can note that the absorption decreases without much
shifting of the Soret band to lower or higher wavelength. This can be explained by the fact
that only electrostatic interactions are taking place. It can also be noted that the absorption
band is not sharp and that it tends to broaden as it reaches saturation.
Figure 42 shows the titration of TEPPI (free) versus TEPPI + d(T4 G4 ). As can be
noted, the absorbance and wavelength increases and the absorbance remains broad. This
phenomena could be due to the electrostatic interactions taking place and also due to
complete saturation of the ligand around the major and minor grooves of the DNA
(quadruplexes do not have grooves as such).
When either zinc or cobalt is incorporated into the ring system as depicted in Figure
51 and 61 respectively and titrated in the presence of d(T4 G4), a similar pattern is obtained
and characterized by a broad absorption band followed by shifting to higher wavelength in
the red region. When the titration is conducted in the presence of d(G4 T4 G4), as depicted by
Figures 43, 53 and 63 and going from TEPPI, ZnTEPPI and CoTEPPI respectively, one can
note that as you titrate, the absorbance tends to increase and the Soret bands shifts to a longer
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wavelength, except for CoTEPPI where the absorption tends to increase without any shifting
of the Soret band to either lower or higher wavelengths. This could be due to electrostatic
interactions between the DNA phosphate groups and the charged centers on the
porphyrazines.
In examining the interaction between TEPPI, ZnTEPPI and CoTEPPI with
d(G2 T2 G2 TGTG2 T2 G2 ), Figures 45, 55 and 65, one can note that the absorption band for
TEPPI and ZnTEPPI are broad and that there is no significant shift of the Soret band, as for
CoTEPPI the soret band remains sharp and decreases substantially as the DNA becomes
saturated with ligand. This same pattern is seen as you change the oligonucleotide to d(T4 G4 ),
as shown in Figures 47, 57 and 67, the Soret band broadens and shifts to a higher wavelength
for TEPPI and ZnTEPPI, but for CoTEPPI the Soret band remains sharp and does not
broaden. Figure 69 shows the % hypochromicity (+) and % hyperchromicity (-) of the Soret
band. The results indicate that calf thymus, d(T4 G4 ), d(T4 G4 T), and d(G2 T2 G2 TGTG2 T2G2 )
show hypochromicity and that d(G4T4 G4) shows hyperchromicity indicating outside stacking
by the metallated and unmetallated porphyrazines.
The effects of DNA on the change of wavelength and spectral properties of
porphyrarines are collected in Table 3. It indicates that d(G2 T 2G2TGTG2T2 G2 ) does not effect
any change in the

for TEPPI and CoTEPPI, but ZnTEPPI does show a shift in the XmaX.

Calf thymus does not effect any change in

when studied against CoTEPPI, but when

studied against TEPPI and ZnTEPPI it shifts the soret band significantly. Based on these
studies it can be concluded that TEPPI, ZnTEPPI and CoTEPPI
oligonucleotides. Competitive dialysis (see Figure

86

bind with DNA

) studies indicate that the apparent

binding K^pp, is relatively low, suggesting that the binding is due to electrostatic interactions.
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Interaction of TEPPI with d(T4G4 ):

a

2.00E-01

Wavelength (nm)

Figure 41. UV/VIS spectra for the titration of TEPPI in the presence of
dCT4 G4).

DNA + DRUG
DRUG

B

2.00E-01

Wavelength (nm)

Figure 42. UV/VIS spectra of d(T4 G4) + TEPPI fully bound and TEPPI
unbound.
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Interaction of TEPPI with d(G4T4G4 ):

Wavelength (nm)

Figure 43. UV/VIS spectra for the titration of TEPPI in the presence of
d(G4 T4 G4).
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Figure 44. UV/VIS spectra of d(G4 T4G4) + TEPPI folly bound and TEPPI
unbound.
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Interaction of TEPPI with d(G2 T2G2TGT G2T2G2):

»

2.00E-01

Wavelength (nm)

F ig u re

45. UV/VIS spectra for the titration of TEPPI in the presence of
d(G2T2 G2TGT G2T2 G2).

DNA + DRUG
DRUG

Wavelength (nm)

F ig u re

46. UV/VIS spectra of d(G2 T2 G2TGT G/TsGO+TEPPI fully
bound and TEPPI unbound.
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Interaction of TEPPI with d(T4G4 T):

Wavelength (ran)

Figure 47. UV/VIS spectra for the titration of TEPPI in the presence of
dCT4 G4T).

DNA + DRUG
DRUG

Wavelength (nm)

Figure 48. UV/VI spectra of d(T4 G4T) + TEPPI folly bound and
TEPPI unbound.
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Interaction of ZnTEPPI with calf thymus:

Wavelength (nm)

F ig u re

49. UV/VIS spectra for the titration of ZnTEPPI in the presence of
calf thymus DNA.

DNA + DRUG
DRUG

Wavelength (nm)

F ig u re 50.

UV/VIS spectra of calf thymus D N A + ZnTEPPI fully bound and
ZnTEPPI unbound.
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Interaction of ZnTEPPI with d(T4G4):

Wavelength (nm)

F ig u re

51. UV/VIS spectra for the titration of ZnTEPPI in the presence of
d(T4 G4).

DNA + DRUG
DRUG

4 00

Wavelength

F ig u re 52.

(nm)

UV/VIS spectra of d(T4 G4) + ZnTEPPI fully bound and
ZnTEPPI unbound.
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Interaction of ZnTEPPI with d(G4T4G4):

W avelength (nm)

Figure 53. UV/VIS spectra for the titration of ZnTEPPI in the presence of
d(G4 T4 G4).

DNA + DRUG
DRUG

Q

2.00E-01

Wavelength (nm)

F ig u re 54.

UV/VIS spectra of d(G4 T4 G4) + ZnTEPPI fully bound and
ZnTEPPI unbound.
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Interaction of ZnTEPPI with d(G2T2 G2TGTG2 T2G2):

Wavelength (nm)

Figure 55. UV/VIS spectra for the titration of ZnTEPPI in the presence of
d(G2T2 G2TGTG2T2 G2).

DNA + DRUG
DRUG

Wavelength (nm)

Figure 56. UV/VIS spectra of d(G2T2 G2TGTG2T2 G2) + ZnTEPPI fully
bound and ZnTEPPI unbound.
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Interaction of ZnTEPPI with d(T4G4 T):

Wavelength (nm)

F ig u re

57. UV/VIS spectra for the titration of ZnTEPPI in the presence of
d(T4 G4 T).

DNA + DRUG
DRUG

Wavelength (nay

F ig u re

58. UV/VIS spectra of d(T4 G4T) + ZnTEPPI fully bound and
ZnTEPPI unbound.
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Interaction of CoTEPPI with Calf Thymus DNA:

J 2.0QE-01

W a v e le n g th (nm)

Figure 59. UV/VIS spectra for the titration of CoTEPPI in the presence of
calf thymus DNA

n

DNA + DRUG
DRUG

2.00E-01

Wavelength (nza)

Figure 60. UV/VIS spectra of calf thymus DNA + CoTEPPI fully bound and
CoTEPPI unbound.
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Interaction of CoTEPPI with d(T4G4):

0.4 -i
0.35 0.3 -

S0-2510

1
|

02 "
0.15 0.05 300

700

500
Wavelength

F ig u re 61.

900

(nm)

UV/VIS spectra for the titration of CoTEPPI in the presence of
d(T4 G4).

DNA +
DRUG
DRUG

-0.1 -I

Wavelength (nm)

F ig u re 62.

UV/VIS spectra of d(T4G4) + CoTEPPI fully bound and
CoTEPPI unbound.
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Interaction of CoTEPPI with d(G4 T4 G4 ):

Wavelength

(nm)

Figure 63. UV/VIS spectra for the titration of CoTEPPI in the presence of
d(G4T4 G4).

DNA + DRUG
DRUG

Wavelength (nm)

Figure 64. UV/VIS spectra of d(G4T4 G4) + CoTEPPI fully bound and
CoTEPPI unbound.
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Interaction of CoTEPPI with d(G2 T2 G2 TGTG2 T2G2 ):

W a v e le n g th

F ig u re 65.

(nm)

UV/VIS spectra for the titration of CoTEPPI in the presence of
d(G2T2G2TGTG2T2G2).

DNA + DRUG
DRUG

Wavelength (nm)

F ig u re

6 6

. UV/VIS spectra of d(G2 T2 G2TGTG2T2 G2 ) + CoTEPPI folly
bound and CoTEPPI unbound.
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Interaction of CoTEPPI with d(T4G4 T):

I.0OE-O1

Wavelength (nm)

Figure 67. UV/VIS spectra for the titration of CoTEPPI in the presence of
d(T4 G4 T).

DNA + DRUG
DRUG

Wavelength

(nm)

Figure 68. UV/VIS spectra of d(T4 G4T) + CoTEPPI fully bound and
CoTEPPI unbound.
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TEPPI
H c a lf thymus
■T4G 4
MT4G4T
■G 4T4G 4
□(G2T2G2)2TGT

MnTEPPI

CoTEPPI

CuTEPPI

ZnTEPPI
-40

-20

20

40

60

80

Figure 69. % Hypochromicity (+) and % Hyperchromicity (-) of the Soret
band For TEPPI, MnTEPPI, CoTEPPI, CuTEPPI and ZnTEPPI in the
presences of the various DNAs.

Oligonucleotide

TEPPI AA CoTEPPI AA

ZnTEPPI AA

0

28

32

54

23

d(T4 G4 T)

35

1

24

d(G4T4G4)

-32

-1

-25

0

13

Calf thymus

21

d(T4 G4)

d (G2 T2 G2 TGTG2 T2 G2 )

0

Table 3. Effects on DNA on the change of (AA) spectral properties of porphyrazines
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AFM Results:
AFM Images of CuTEPPI were measured at 10 pM, 20 jxM, 30 pM, 60 pM, 100 pM
and 300 pM concentration. It was determined that at these concentrations the length of
linearized plasmid prS316 did not change as indicated by Figures 70 -76. Also, AFM Images
of CoTEPPI at 10 uM, 30 uM, and 524.5 uM in the presence of linearized plasmid prS316 did
not change the length of DNA as shown in Figures 77 - 79. It was also shown that AFM
Images of MnTEPPI, ZnTEPPI and TEPPI at 300 uM concentration did not change the length
of linearized plasmid prS316 (See Figures 80 - 82). Based on our findings we determined
that porphyrazines, either nonmetallated or metallated, do not increase the length of
linearized plasmid pRS316 which contains 4887 base pairs (see Figure 83). Initial studies
comparing the DNA lengthening with CoTEPPI and CuTEPPI to the ethidium bromide
theoretical curve indicated that there was no change in the DNA length as shown in figure 84.
In order to see if increasing the concentration of porphyrazine from 10 uM to 300 uM would
affect the length of the DNA, we found that increasing the concentration of the porphyrin
does not change the length of the linearized plasmid DNA. What one can note that when
increasing the concentration of porphyrazine, nodes form at different length intervals within
the DNA strand. Competitive binding studies done by Bottomley indicated that porphyrazines
TEPPI, ZnTEPPI and CoTEPPI, in the presence of ethidium bromide, a well known
intercalator of linearized plasmid pRS316 displaced the ethidium bromide after reaching
equilibrium Our future work will be to develop a DNA strand in which we can form
quadruplexes at certain length intervals within the DNA strands.
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SAM PLES O F IM A G ES FR O M EACH G RO U P

Control pltS316 DMA (not treated)

F ig u re

70.

(-*887BP)

AFM image of control linearized plasmid prS316.

10 uMR-68 (( 'it Porphyrazine)

F ig u re 71.

AFM of CuTEPPI at KtyM in the presence of linearized
plasmid prS316.
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20 u M li-68 (Cu Porphyraime)

Figure 72. AFM of CuTEPPI at 20 nM in the presence of linearized
plasmid prS316.
30 uM It-68 (Cu Porphyrazine)

Figure 73. AFM of CuTEPPI at 30
plasmid prS316.

in the presence of linearized
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60 uM H-68 (Cu Porptyrazine)

Figure 74. AFM of CuTEPPI at 60 uM in the presence of linearized
plasmid prS316.
100 uM R-68 (Cu Parphyruzine)

Figure 75. AFM of CuTEPPI at 100 fiM in the presence of linearized
Plasmid prS316.
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300 uM Il-ffS (Cu Porphyra-me)

Figure 76. AFM of CuTEPPI at 300 uM in the presence of linearized
plasmid prS316.
10 uMR-H7 (Co Porphyrasine)

Figure 77. AFM of CoTEPPI at 10 ^M in the presence of linearized
plasmid prS316.
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30 uM R -87 (Co Porphyrasine)

Figure 78. AFM of CoTEPPI at 30 uM in the presence of linearized
plasmid prS316.

524.5 uMR-87 (Co Porphyrazine)

Figure 79. AFM of CoTEPPI at 524.5 ^M in the presence of linearized
plasmid prS316.
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300 u M R S J (hin Porphyrazine)

Figure 80. AFM of MnTEPPI at 300 uM in the presence of linearized
300 uM R-85 (Zn Porphyrazine)

Figure 81. AFM of ZnTEPPI at 300 uM in the presence of linearized
plasmid prS316.
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300 uM R-98 (No Metal Center Porphyrazine)

Figure 82. AFM of CoTEPPI at 300 aM in the presence of linearized
plasmid prS316.
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NUMBER OF STRANDS (%)
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I

30
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■TEPPI
■M nTEPPI
■ C oT E PPI
□ C uT E P P I
□ Z nT E PPI
■ E X P B-DNA Len

i
§
JL

I

1.251.351.451.551.651.75 1.8
DNA LENGTH (um)

Figure 83. # DNA strands (%) versus DNA length (um) from porphyrazine study
using AFM. (Bottomley, 2004).
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Comparison of DNA LM gthsning from R-87(Co) and R-81(Cu) lo Tha Etfiidium
Bromida Theoretical Binding Curve
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Figure 84. Comparison of DNA lengthening from CoTEPPI and
CuTEPPI to the ethidium bromide binding curve.
(Bottomley, 2004).
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Competitive Dialysis studies:

Our results as shown by Figure 83, indicate that porphyrazines do not bind to single
stranded poly (dA) or poly (dT) DNA. Figure 84 indicates that we have also found that
double stranded poly (dG-dC) and poly (dA-dT) DNA have a low binding affinity (K.app) to
MnTEPPI, CoTEPPI, CuTEPPI, ZnTEPPI and TEPPI. We have also found that MnTEPPI
and ZnTEPPI show a greater binding affinity relative to calf thymus DNA (Figure 85) when
comparing the difference in the amount of bound relative to the amount bound to calf thymus
Cb - Cb CTDNA. On the contrary, the data in Figure

86

indicate that MnTEPPI, CoTEPPI,

CuTEPPI, ZnTEPPI and TEPPI have a greater affinity for quadruplex structures as indicated
by the difference in the amount of bound relative to the amount bound to G4T4, (Cb - Cb
T G \

4 4J-
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(uM) Bound
oligonucleotides
■poly (da)
■poly (dt)
■poly (dg-dc)
■poly(da-dt)
□calf thymus
□T4G4
■T4G4T
■G4T4G4
■(G2T2G2)2TGT
■Blank

MnTEPPI CoTEPPI CuTEPPI ZnTEPPI

TEPPI

Figure 85. Competitive dialysis diagram showing bound (uM) porphyrazine
to oligonucleotide DNA
0.12
oligonucleotides
■ p o ly (da)
■ p o ly (dt)
■ p o ly (dg-dc)
■ p o ly (d a-d t)
□ c a lf thym us
O T4G 4
■ T4G 4T
■G 4T4G 4
■ (G 2 T 2 G 2 )2 T G T

MnTEPPI CoTEPPI CuTEPPI ZnTEPPI

TEPPI

Figure 8 6 . Apparent binding constant KaPP diagram of porphyrazine
for each oligonucleotide of DNA.
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oligonucleotides
■ p o ly (da)
■ p o ly (dt)
■ p o ly (dg-dc)
■poly(da-dt)
E3calf thymus
□T4G 4
■T4G 4T
■G 4T4G 4
■(G 2T2G 2)2TG T

MnTEPPI CoTEPPI CuTEPPI ZnTEPPI

TEPPI

Figure 87. (Cb - Cb CTDNA) = The difference in the amount bound
(pM) relative to the amount bound (pM) to calf thymus DNA.

oligonucleotides
■poly (da)
■poly (dt)
■poly (dg-dc)
■poly(da-dt)
□ calf thymus
□T4G4
■T4G4T
■G4T4G4
B(G2T2G2)2TGT

MnTEPPI CoTEPPI CuTEPPI ZnTEPPI

TEPPI

Figure 8 8 . (Cb - Cb W ) = The difference in the amount bound (pM)
relative to the amount bound (pM) to d(T4 G4).
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Utility of Porphyrazines as HIV inhibitors:

Reverse transcriptase (RT) plays a key role in the replication of HIV by converting
single-stranded genomic RNA into double-stranded proviral DNA and represents one of the
main targets for the development of AIDS therapy. Most inhibitors of RT described in the
past years, whether nucleoside analogues or nonnucleoside inhibitors target the polymerase
activity of RT but present some limitations including toxicity and die emergence of resistant
strains of HIV.
The FDA has approved 16 drugs for treatment of HIV infection, and ten of these
target the DNA polymerase activity of reverse transcriptase. The downfall is that multi drug
resistant HIV strains are becoming increasingly common. Many of these strains are also
resistant to most other drugs that are being developed, since these are directed at the same
target as the approved drugs. Thus, identification of novel compounds that inhibit HIV targets
is essential. In this context, HIV RT-associated RNase H has not been fully researched. Only
a few inhibitors of HIV RNase H have so far identified and of those most have poor potency,
lack "drug-like" properties, or lack antiviral activity. Only two are readily amenable to
medicinal chemistry, die N-acyl hydrazones and the aryl hydrazones, and both classes of
inhibitors have problems that may preclude further development. A major barrier to the
discovery of RNase H inhibitors is the lack of a suitable assay. Commonly used assays are
cumbersome, time-consuming and unsuitable for high-throughput screening (HTS) of large
chemical libraries. Pamiak has developed a fluorescence resonance energy transfer (FRET)
assay that allows high-throughput robotics screening for inhibitors of HIV RNase H. 230 This
assay was designed to measure non-specific RNA cleavage reactions in order to be useful in
secondary screens with human RNase H. The assay is suitable for both 96-well and 384-well
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microplate formats. His group has screened several different chemical libraries with the
FRET RNase H assay and shown that the assay is robust, precise (coefficient of variation
about 6 %, Z-factor of 0.8), provides an excellent "hit rate" (about 0.5%), and yields data
comparable to that obtained in standard gel assays. These screens have identified several new
structural classes of RNase H inhibitors including those based on the mappicine
pharmacophore, a structure highly amenable to combinatorial synthetic approaches that allow
focused structural modifications designed to improve inhibitory potency. The FRET assay
has also facilitated development of our N-acyl hydrazone RNase H inhibitors, especially
reduced-toxicity analogs that will be useful in resistance studies. Pamiak’s group screened
our porphyrazines using this high-throughput screening FRET assay for RNase H activitity.
The results are summarized in Figure 89. Based on this assay, at a 10 uM concentation of
porphyrazine, it was determined that TEPPI and ZnTEPPI are relatively potent inhibitors of
this HIV activity at 92% and 83% inhibition, respectively. The other porphyrazines,
MnTEPPI (17%), CuTEPPI (25%), CoTEPPI (12%) did not show high inhibition of HIV
reverse transcriptase-associated ribonuclease H activity. These same porphyrazines were also
tested at 6 uM concentation. The results are also shown in Figure 89. At this concentration it
was found that TEPPI had a 98% inhibition of HIV activity, followed by TEPPC1 at 80%
inhibition, followed by MgTEPPI having a 65% inhibition of HIV activity. Cytotoxicity was
measured in cell cultures by Dr. Pamiaks laboratory. The values to compare are the antiviral
data (Figure 90) with the cytotoxicity data (Figure 91) as indicated by Figure 92. The ratio of
CC50/EC50 gives the theurapeutic index: the higher this ratio, the better the candidate for
targetting the virus. What can be summarized about porphyrazines is that they are potent RT
inhibitors. They have also shown to inhibit the isolated RNase domain fragment. One of the
drawbacks is the high cytotoxicity, hence they could be used as microbicides. The solubility
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in water and the above findings will help in designing new and less toxic molecules with high
inhibition activity.

■ % Inhibition HIV RT at 10 uM
■ % Inhibition HIV RT at 6 uM

Figure 89. Intact Reverse transcriptase Rnase H % inhibition at 6 pM and
10 pM concentration. (Pamiak 2004).

Figure 90. Concentration of Porphyrazine required for 50% inhibition
of viral replication of HIV infected cells. (Pamiak 2004).
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■Cytotoxicity CC50 (uM)

^

G°

G*

^

*

Figure 91. Concentration of porphyrazine required for 50% cell kill
of the uninfected cells. (Pamiak 2004).

■Theurapeutfc Index
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Figure 92. CC50/EC50 measure of the porphyrazine theurapeutic index.
(Pamiak 2004).
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CHAPTER V
CONCLUSION

The sole purpose of our study was to synthesize new novel nonmetallated and metallated
quatemized porphyrazines and assess their utility as potential drugs for the treatment of cancer
and AIDS. First, we were able to synthesize new novel porphyrazines using inexpensive
materials which required no elaborate process equipment, while obtaining good yields and high
purity compounds. The reason why we obtained one isomer of tetrapyridino porphyrazine (TPP)
is supported by the fact that the carbon of the nitrile at the para position of 3,4-pyridinedicarbonitrile has different reactivity than the carbon of the nitrile at the meta position due to
resonance effect. This in turn makes the carbon of the nitrile at the para position more positively
charged and susceptible to nucleophilic attack. This difference in reactivity obtained results in
obtaining one isomer in the tetramerization process which is also supported by the UV/visible
spectra obtained in Figure 37. Secondly, we were able to demonstrate through UV/visible
studies, atomic force microscopy, and competitive dialysis that these molecules interact with
DNA oligonucleotides. Finally, Dr. Michael Pamiak, at the Division of Infectious Diseases
(University of Pittsburgh, Pittsburgh, PA) used a fluorescence resonance energy transfer assay
that allowed high throughput robotic screening of HTV Rnase H. The assay was designed to
measure non-specific RNA cleavage reactions rather than the specific cleavage reactions of
polypurine tract generation. We were able to demonstrate that porphyrazines inhibit reverse
transcriptase Rnase H in the aids vims.
Recently, cationic porphyrins have been shown to demonstrate qualities that make these
compounds useful as photosensitizers for a large number of biological systems.
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Cationic

porphyrins are able to interact with DNA bases, inducing DNA lesions upon photoactivation. 231
Also, the combination of hydrophobic and hydrophilic substituents in the porphyrin structure
results in an intramolecular polarity axis, which can facilitate membrane penetration. This
combination produced a better accumulation in subcellular compartments and enhanced the
effective photosensitization. 2 3 2
The porphyrazines that we synthesized in our laboratory have shown to exhibit high
absorbances at higher wavelengths in the range of 600 - 700 nm, making them viable candidates
as photodynamic theurapeutic agents within the photodynamic window for the treatment of
tumor cells. Another property that makes these molecules good candidates as photodynamic
theurapeutic agents is that they are able to absorb even at 5 X10"6 molar concentrations and that
they are water soluble. One of the goals of our group is to continue to synthesize porphyrazines
that offer better photophysical and biological properties.
The synthesis of these new porphyrazines has also shown they are viable vehicles for
the inhibition of reverse transcriptase from the HIV virus as demonstrated by Figure 89. Even at
a very low concentration of 6 pM, porphyrazines have inhibited reverse transcriptase Rnase H.
Porphyrazines required low concentrations, 12 pM to 2 pM, to inhibit 50% of viral replication
of HIV infected cells as depicted in Figure 90.
What was found to be promising is that porphyrazines require a higher concentration to
kill 50% uninfected cells as shown in Figure 91. When examining the theurapeutic index, which
is the ratio of CC50/EC50, one noted that MnTEPPI has the highest theurapeutic index as
depicted from Figure 92. What can be concluded about porphyrazines as potential drugs, is that
future work must focus itself upon synthesizing porphyrazines with functional groups that offer
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high inhibition at a low concentration, making the theurapeutic index higher. Another future area
of interest will be to synthesize porphyrazines with other functional groups such as sugars and
steroids while at the same time making them quatemized, to offer a better vehicle through the
cell membrane. Another possible area for these porphyrazines could be utilized in inks or as
sensitizers for magnetic media. As research continues in the field of phthalocyanines, chemo-,
regio-, and even stereoselective synthetic methods will be developed as suitably fimctionalized
systems. Chiral analogues of many phthalocyanine derivatives can be expected to be synthetic
targets in the near future. The greater chemical flexibility of related porphyrazines will also help
facilitate the selective synthesis of low-symmetry single compounds.
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